**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 57854

**Manuscript Type:** REVIEW

**Perspectives of pluripotent stem cells in livestock**

Kumar D *et al*. Pluripotent stem cells in livestock

Dharmendra Kumar, Thirumala R Talluri, Naresh L Selokar, Iqbal Hyder, Wilfried A Kues

**Dharmendra Kumar, Naresh L Selokar,** Animal Physiology and Reproduction Division, ICAR-Central Institute for Research on Buffaloes, Hisar 125001, India

**Thirumala R Talluri,** Equine Production Campus, ICAR-National Research Centre on Equines, Bikaner 334001, India

**Iqbal Hyder,** Department of Physiology, NTR College of Veterinary Science, Gannavaram 521102, India

**Wilfried A Kues,** Department of Biotechnology, Friedrich-Loeffler-Institute, Federal Institute of Animal Health, Neustadt 31535, Germany

**Author contributions:** Kumar D and Kues WA drafted and wrote the review; Talluri TR designed the figures; Hyder I and Selokar NL contributed to specific chapters; all authors read and approved the final version of the manuscript.

**Corresponding author: Dharmendra Kumar, PhD, Senior Scientist,** Animal Physiology and Reproduction Division, ICAR-Central Institute for Research on Buffaloes, Hisar 125001, India. dharmendra.kumar@icar.gov.in

**Received:** June 26, 2020

**Revised:** September 28, 2020

**Accepted:** November 9, 2020

**Published online:**

**Abstract**

The recent progress in derivation of pluripotent stem cells (PSCs) from farm animals opens new approaches not only for reproduction, genetic engineering, treatment and conservation of these species, but also for screening novel drugs for their efficacy and toxicity, and modelling of human diseases. Initial attempts to derive PSCs from the inner cell mass of blastocyst stages in farm animals were largely unsuccessful as either the cells survived for only a few passages, or lost their cellular potency; indicating that the protocols which allowed the derivation of murine or human embryonic stem (ES) cells were not sufficient to support the maintenance of ES cells from farm animals. This scenario changed by the innovation of induced pluripotency and by the development of the 3 inhibitor culture conditions to support naïve pluripotency in ES cells from livestock species. However, the long-term culture of livestock PSCs while maintaining the full pluripotency is still challenging, and requires further refinements. Here, we review the current achievements in the derivation of PSCs from farm animals, and discuss the potential application areas.

**Key Words:** Livestock; Cellular reprogramming; Chimera; Cell-therapy; Ontogenesis; Pluripotency

Kumar D, Talluri TR, Selokar NL, Hyder I, Kues WA. Perspectives of pluripotent stem cells in livestock. *World J Stem Cells* 2020; In press

**Core Tip:** The successful derivation of pluripotent stem cells (PSCs) from livestock represents an ideal model for the progress of veterinary, biomedical and regenerative medicine. The inherent properties of self-renewal and differentiation make PSCs an ideal raw biomaterial for innovative approaches in artificial reproductive techniques, cell-based therapy, disease modelling, drug testing, organ generation, breed conservation and *in vitro* meat production. In this review, we present the current status of PSCs application for the development of livestock farming and their potential applications for human welfare.

**INTRODUCTION**

Pluripotent stem cells (PSCs) have the capability to self-renew and to develop into the three primary germ cell layers and therefore can form all cells and tissues of the adult body. There are two sources for obtaining PSCs, embryonic stem (ES) cells developed from an embryo, and induced pluripotent stem (iPS) cells derived *via* reprogramming of somatic cells (Figure 1). The process of fertilization, parthenogenetic activation, or nuclear transfer (NT), can lead to zygote formation followed by rapid cleavage divisions, which eventually results in the blastocyst stage with two different cell compartments, the outer trophectoderm and the inner cell mass (ICM). After zygote formation, the embryo undergoes several genetic and epigenetic changes, such as DNA de-methylation and re-methylation, replacement of protamines to histones, telomere extension, histone reprogramming, and first activation of the embryonic genome[1]. The resulting ICM cells in the blastocyst have a transient cellular pluripotency and will later form the embryo proper, and thus are able to develop into all somatic cells of an organism. The first successful derivation of cell cultures from the ICM, which maintain these pluripotent properties *in vitro*, was described in 1981 with murine cells, which were termed ES cells[2,3]. Under specific *in vitro* conditions, such as the culture on feeder cell layers, the pluripotent status of ES cells becomes locked in the Petri dish. The ES cells showed an unlimited proliferative capacity, were able to be maintained in an undifferentiated state of potency (naïve pluripotency), and could be triggered to differentiate into any cell type. Consequently, ES cells developed into an important arsenal for developmental biology, and new reproduction approaches, such as blastocyst complementation assays and generation of cell chimeric animals, or *in vitro* differentiation of desired cell types, including gametes[4,5].

However, translation of the protocols for the derivation of ES cells to livestock species is painfully slow. Almost a decade later in 1990, putative ES cells from the early stages of embryos were reported in domestic livestock species such as sheep, pig and cattle; however, these cells could be maintained only for a few passages[6,7]. Later, ES cell-like lines have been derived from many species of livestock such as pig[8,9], cattle[10-13], sheep[14,15], goat[16,17], horse[18], and buffalo[19,20]; however, detailed characterizations suggested that these putative ES cell cultures seem to be in a primed status of cellular potency.

NT describes the transplantation of a somatic cell or nucleus in an enucleated oocyte, subsequently, the re-constructed zygote is activated and cultured up to the blastocyst stage. This requires successful reprogramming of the donor nucleus by factors accumulated in the cytoplasm of the recipient oocyte. The NT-derived blastocyst can then be used to derive ES cells from the ICM (‘therapeutic cloning’)[21]. NT-ES cell lines have been established in mice[22-24], cattle[21], buffalo[25] and non-human primates[26]. In livestock, NT-ES cells could be derived from genomically selected high value animals with potential use in reproductive cloning or for conservation using cryopreservation of these cell lines[27].

Alternatively, parthenogenetically derived embryos are equally valuable for the generation of ES cells. The first parthenogenetic embryos derived ES (pES) cell lines were established from mice[28]. Thereafter, it was established in other farm animals such as in pig[29], horse[18], sheep[14], cattle and buffalo[30-33]. Muzaffar *et al*[32] successfully established buffalo ES cell lines from blastocysts derived from *in vitro* fertilization, parthenogenesis, and NT. These results suggested that the cell line generated from parthenogenetically derived embryos maintained the ES cell properties and could be used as a model to study the effects of imprinting. However, isolation and characterization of ES cells from livestock species is technically still challenging, as the derived lines showed variable expression patterns of pluripotency markers[34] and may undergo spontaneous differentiation; limited or failed contribution of the transferred ES cells to a chimeric organism in blastocyst complementation assays suggested a limited cellular potency[11,35,36].

In 2008, the 3 inhibitor (3i) approach resulted in the first isolation of authentic rat ES cells[37]. Basically, the 3i approach is an ES culture medium supplemented with three inhibitors of metabolic pathways, which interact with cellular potency: CHIR99021 (GSK3 kinase inhibitor), PD184352 (ERK 1-2 kinases inhibitor), and SU5402 [fibroblast growth factor (FGF) tyrosine kinase receptor inhibitor]. The application of this strategy may allow the generation of genuine PSCs from livestock.

A recent approach is the reprogramming of somatic cells to iPS cells by forced expression of a set of key reprogramming factors such as octamer-binding transcription factor 4 (Oct4), Nanog, MYC proto-oncogene (c-Myc), Kruppel-like factor 4 (Klf4), *etc*[38-41]. Similar to ES cells, iPS cells are characterized by their self-renewal ability, morphological resemblance, expression of stemness gene, epigenetic state, and their differentiation potential toward all somatic cell types including the germ-line. This technique has been swiftly and widely adopted in farm animal species such as pig[42-47], sheep[48-50], goat[51,52], dog[53-56], cattle[57,58], and horse[59-64]. At present, bona fide ES cells from livestock are not yet available, but long-term stable iPS cells have been generated from many species and allow the further optimization of culture conditions.

The majority of generated livestock iPS cells showed classical features of pluripotency, such as *in vivo* differentiation and teratoma formation. It has been claimed that porcine iPS cells can contribute to chimera formation[45]. Similarly, ovine iPS cells also formed chimeric lambs after aggregation with early embryonic stages[65-67]; however, the efficiency of chimera contribution warrants further studies. Nevertheless, the results represent advancements in iPS cell technology and promoted the molecular understanding of livestock pluripotency.

PSCs can also be derived from germline stem cells, a class of unipotent stem cells which reside in testis tissue. Observations made by several researchers that neonatal and adult mouse testis contains spermatogonial stem cells (SSCs) or male germline stem cells, which are phenotypically similar to ES cells, are capable of differentiating into three embryonic germ lineages *in vitro*, form teratomas, and showed germline contribution and transmission[68-71], suggested that the SSCs may retain the ability to generate PSCs. The PSCs derived from these approaches are a useful tool for examining the molecular mechanisms of pluripotency in the male germline. Potentially, the SSCs will be useful for cell-based therapies which benefit males. Similar to SSCs, female germline stem cells (FGSCs) have been proposed to reside in the ovary. Wang *et al*[72] derived FGSCs from ovaries, which exhibited properties similar to those of ES cells in terms of stemness gene expression and differentiation potential. These novel approaches provide new opportunities to study germ cell biology and opens the possibility of using these cells for genetic diseases in various cell lineages and provides a foundation for personalized regenerative applications. Recent research directed at producing artificial germ cells from stem cells of non-germ line cells may offer the possibility of treating infertility in the future[73].

PSCs derived from ES cells, iPS cells or the germ cell lineage may have great potential in veterinary medicine, cell-based therapies, production of pharmaceutical molecules *via* transgenic animals, multiplication of elite animals, conservation of endangered animals and as model animals for effective biomedical applications[74-80]. Previously, several review articles on livestock iPS cells have been published which described methods of cellular reprograming and their potential applications[78-83]. Here, we provide the most current achievements in PSCs from livestock, and discuss the potential applications of PSCs for the development of livestock farming and their potential applications for human welfare.

**CURRENT STATE OF ES CELLS FROM LIVESTOCK**

In general, putative livestock ES cells have been derived from early embryonic stages applying either standard culture systems developed for the culture of murine or human ES cells. However, most livestock ES cells did not maintain robust self-renewal and typically failed to perform in teratoma and blastocyst complementation assays[84,85]. This may be due to differences in the ontogenesis of cell lineage formation between rodent and livestock species. In rodent embryonic development, the first cellular differentiation is initiated at the late morula stage where the outer cells develop into an epithelial structure, followed by blastocoel formation. This leads to the development of two cell lineages, the trophectoderm (TE) and ICM[86]. The ICM differentiates further into the epiblast and the primitive endoderm or hypoblast. The epiblast, hypoblast and TE are common in all mammalian blastocysts, but the timing since fertilization in livestock embryos is relatively delayed compared to the mouse[34,87-89].

In porcine and bovine embryos, the hypoblast cells form on 7/8 d post-fertilization, and the epiblast forms on day 12[90,91]. Therefore, the time points used to isolate ES cells are not equivalent between livestock and rodent counterparts[92]. Also differences in the molecular pathways that control pluripotency between murine and domestic animals have been elucidated[93-95].

The current concept of different pluripotency states, which are termed naïve and primed, is likely to provide new approaches for the derivation of livestock ES cells. A steady progress has been made toward optimizing culture conditions for the derivation of stable and highly potent porcine ES cells[8,96]. More recently, porcine ES cells have been claimed to give rise to the chimeric contribution using a modified medium supplemented with basic fibroblast growth factor and leukemia inhibitory factor; however, follow-up studies with respect to contribution to the germline and formation of functional gametes are warranted[97,98]. Similarly, canine ES cells were derived; these canine ES cells expressed all the pluripotent markers, showed long-term self-renewal, and formed teratomas[99]. Thus, these cell lines exhibited most hallmarks of genuine ES cells, which represent a step toward pre-clinical therapies in large animal models.

However, these efforts on establishing livestock ES cells have not been turned into bona fide ES cell lines that are competent in germ line transmission. Multifactorial reasons may contribute to the lack of success for this relevant aim. First, significant differences in the initial embryonic development in livestock from that in rodents, second, the established pluripotency markers may be less distinct for livestock ES cells, and third, the pluripotency states, naïve *vs* primed, are pretty poorly defined in livestock species[84,100]. Several reviews have been published on the topic of ES cells in livestock covering isolation stages, culture condition, differentiation, proliferation properties and characterization[85,89,92,101-103]. These reviews summarized our knowledge on livestock ES cells. Table 1 summarizes some of the most recent observations that have been reported for ES cells from livestock.

**CURRENT STATE OF** i**PS CELLS FROM LIVESTOCK**

A ray of hope was the development of reprogramming techniques to obtain iPS cells from somatic cells[38]. Recent advances in iPS cells technology may overcome the bottleneck of establishing pluripotent cells from livestock species, and demonstrate that iPS cells showed advanced level of pluripotency, such as the ability to differentiate *in vitro* into multi lineages and *in vivo* into teratomas and chimeras[79,104]. The production of chimeric livestock from iPS cells would open the possibility to genetically engineer farm animals to improve traits of agricultural importance, and the generation of biomedical models[45,67,105].

The current knowledge on stemness gene regulation in ES cells helps to execute iPS cells in a better way, and could allow the development of approaches closer to clinical application. Transcriptional profiling of ES cells revealed that factors such as Oct4, Nanog, sex determining region Y-box 2 (Sox2), Klf4, c-Myc and Lin28 are essential to maintain pluripotency[106,107]. Among these factors, Oct4, Nanog and Sox2 have been identified as core transcription factors, showing both spatial and temporal expression in cultured PSCs and pluripotent cells of the ICM[108-110]. These core transcription factors also play pivotal roles in regulation of the pluripotent gene expression and simultaneous suppression of many genes related to differentiation[111,112]. They exert their functions by co-occupying their target genes, and can bind at their own and each other’s promoters to form an interconnected auto-regulatory loop[111,113]. These three factors function collaboratively in an auto-regulatory circuitry fashion to maintain their own expression and maintain the pluripotency of ES cells[106,114]. Additionally, Nanog was identified as the key factor, which regulates the establishment of the pluripotent epigenome[115,116]. The role and mechanism of these transcription factors in the reprogramming of livestock somatic cells to iPS cells have been reviewed[78,81,104,117].

Several strategies have been applied to deliver core reprogramming factors such as genes, mRNAs and proteins into somatic cells for the derivation of iPS cells. Alternatively, the replacement of reprogramming factors by small chemical agents has also been assessed. Commonly, retro- and lenti-viral approaches were employed for cellular reprogramming of different types of somatic cells from livestock such as pig[105], cattle[57,118-120], sheep[67], goat[51,121], dog[54,56], horse[63] and buffalo[65]. Recently, for the first time, cat iPS cells were created using disarmed retroviruses with the coding sequences for human Oct4, Sox2, Klf4, cMyc, and Nanog[122]. The expression of ectopic factors can be temporally confined by employing inducible promoters or viral promoters, which are epigenetically silenced. Shortcomings of the viral approach include the limited cargo capacity of approximately 7 kb for the transduced genes, the induction of innate immune responses, potential genotoxic effects, which limit the translation into clinical trials[123], and increased safety methods.

To evade these safety concerns, remarkable technological progress has resulted in the establishment of non-integrating viral and non-viral approaches, but limited attempts have been made to apply these to cells from livestock species. For example, the non-integrating adeno- and Sendai-viruses demonstrated efficient production of human, murine and canine iPS cells[124-127]. Apart from viral-mediated derivation of livestock iPS cells, non-viral approaches such as plasmid vectors, recombinant proteins, transposons, minicircle DNAs, small molecules, and mRNAs are in use to eliminate the risk of genomic alteration and enhance the prospects of iPS cells. In this regard, bovine iPS cells were successfully derived by plasmid[128], and transposon systems[58,129,130]. Similarly, porcine iPS cells were also established using episomal[131,132], and transposon systems[47], the transposon systems have been attempted to derive equine[59] and buffalo[66] iPS cells. Detailed information on approaches to generate transgene-free iPS cells has recently been reviewed by Haridhasapavalan *et al*[82]. Most recent studies of iPS cells derived from livestock are shown in Table 2. In addition, extensive overviews of iPS cells produced from a wide range of animal species including livestock with their prospective applications and limitations have been recently reviewed[85,103,133]. Most recently, our group presented the potential applications of transposon-mediated derivation of iPS cells for cell-based therapies[83].

**POTENTIAL APPLICATIONS OF PSC**s **FROM LIVESTOCK**

***Reproduction***

A long-standing goal of PSCs research is the differentiation into functional germ cells, and their application for *in vitro* fertilization to obtain sexually recombined genotypes. In combination with the readout of genomic trait values from few cells *via* single nucleotide polymorphism chips and whole genome sequencing techniques this will dramatically improve the breeding process[134]. In mammals, germ cells originate from PGCs, the PGCs are initially specified outside the post-implantation embryo through gradients of Wnt family member 3 (WNT3) and bone morphogenetic proteins (BMPs)[135-137]. After that PGCs migrate to the genital ridges, where they settle and ultimately make gametes. The PSCs are principally immortal, with a high proliferative rate, and the ability to differentiate into gametes that could enable *in vitro* breeding schemes for accelerated genetic improvement in livestock. Under the conventional breeding scheme of dairy animals, the generation interval for sire(s) or dam(s) of bulls is approximately ± 5 years. This time period could be considerably reduced to about 2.5 years using genomic selection approaches[134,138]. Recently, a proposed parental embryos to offspring embryos breeding system will require approximately 2 mo to finish one round of selection, and annual genetic gain will increase approximately 10-fold as compared to the standard genomic selection in dairy animals[for review see, 134,139]. However, the feasibility of applying this approach to farm animals needs to be proven in field studies.

So far the proof of principle has been provided in rodents, where sperm and oocytes were generated by the differentiation of male or female PSCs[140,141]. These works support the notion that this approach might be translatable to farm animals. However, before the proposed breeding system can be applied in farm animals a series of obstacles need to be overcome. Earlier, it was observed that monkey ES cells could differentiate into primordial germ cell-like cells (PGCLCs) and their differentiation ability was further improved by supplementing a conditioned medium from testicular or ovarian cells with recombinant BMP4, retinoic acid (RA), or stem cell factor[142,143]. Another study showed the possibility of spermatogonial stem cell transplantation in a non-human primate infertility model[144]. The findings laid the basis for the development of future germ cell regeneration in livestock. Recently, the derivation of stable bovine ES cells was reported, which could offer a technical basis for the auxiliary establishment of *in vitro* germ cell induction in farm animals[145]. Porcine iPS cells have been successfully differentiated into PGCLCs, and xenotransplantation of these cells into the testes of infertile immune-deficient mice resulted in immunohistochemically identifiable germ cells[146,147]. Another study revealed that porcine PGCs could be derived from the posterior pre-primitive-streak epiblast by upregulation of SOX17 and B-lymphocyte-induced maturation protein 1 through activation of WNT and BMP signaling pathways[148]. A number of comprehensive studies dedicated to bovine germ cell differentiation suggested that RA and/or BMPs are important for induction of PSCs[149]. The significance of RA in gametogenesis and meiosis induction has also been reported in buffalo[150,151].

Apart from reduction of the generational interval using *in vitro* breeding in livestock, the idea of generating gametes *in vitro* may translate to treatments of infertility, understanding the complexity of gametogenesis, and it could also be a source for regenerative medicine[78,152]. Improvements in germ cells differentiation of PSCs from livestock will further fuel the enthusiasm of researchers working on farm animals (Figure 2). If robust and field-applicable protocols for *in vitro* germ cell differentiation of livestock PSCs could be developed, an *in vitro* breeding program will rapidly be implemented.

More recently, haploid stem cells (hSC), having a single set of chromosomes, are considered excellent tools to study gene function (due to having a single copy) and obviate the mutation effect[153]. To date, hSCs have been derived from mouse, rat, monkey and humans[153,154]. In nature, ova and sperm are haploid cells. Experimentally it has been shown that it is possible to generate murine hSCs containing only the maternal genome or the paternal genome through either parthenogenetic or androgenetic embryos. Recently, it was demonstrated that fertile adult mice can be produced after fertilization of a sperm with an ovum derived from haploid ES cells[155], supporting the significance of haploid stem cells as a new tool to quickly generate genetic models for the direct transmission of genomic modifications at the organism level.

***Genetic engineering***

The genetic engineering of animals refers to adding, changing or removing certain DNA sequences, and the inheritance of these modifications to the next generation. The self-renewal and differentiation ability of PSCs make these cells an attractive tool for genetic engineering for various downstream applications. The self-renewal property of PSCs means they are theoretically immortal *in vitro through* symmetric cell divisions, which could provide a possibility for genetic modification and screening of cells, carrying the intended gene modifications.

Usually, genetic modification requires several generations and a large number of animals that could be overcome using PSCs especially in livestock *via* contribution to the germline[156]. The PSCs can be genetically modified *in vitro* and then injected into an embryo where they contribute to the germline, resulting in transgenic offspring (Figure 3) and thus reducing the required number of animals to produce the line founders[157].

In murine ES cell-based targeted mutagenesis, homologous recombination (HR) approaches allow the loss-of-function, gain-of-function experiments of desired loci, but also more complex genetic modifications, such as large genetic recombinations, as well as spatial and temporal expression patterns[158-160]. Using this technology, mouse ES cells can be screened and single colony-derived cells produced to employ for blastocyst complementation. However, in livestock due to the lack of bona fide ES cells, the efficiency of HR events is very low. Richt *et al*[161] produced cattle with knock-out of the prion gene using somatic cell nuclear transfer (SCNT) combined with HR in somatic cells. Details of several genetic engineering methods used for successful creation of modified PSCs including ES and iPS were reviewed[162].

Previously, many workers reported that the use of ES cells as donor nuclei in SCNT resulted in higher birth rates as compared to differentiated somatic cells[25,163], which may be due to the un-differentiated state of PSCs. An advantage of this approach is that homozygous transgenic founders are produced in one generation. The use of iPS cells derived from livestock to produce offspring by SCNT has so far resulted in low success rates. Attempts to clone pigs and sheep using iPS cells resulted in very low efficiencies[121,164,165], whereas in murine experiments cloned animals were produced with similar efficiency using iPS or ES cells[163,166].

It was assumed that the forced expression of exogenous factors in iPS cells may hamper the nuclear reprogramming of donor cells during SCNT[121]. For this reason the possible applications of PSCs for generating genetically modified livestock have been limited. The recent discovery of site-specific nucleases such as zinc finger nucleases, transcription activator-like effector nucleases and CRISPR-Cas9 has allowed us to overcome the bottlenecks of genetic engineering in livestock[167-171]. The detailed description of site-specific nucleases is beyond the scope of the current manuscript, and interested readers can find excellent reviews elsewhere[156,172].

***Models for cell therapy***

Blood stem cell transplantation is a well-established clinical treatment of leukemias[173]. Nowadays, the feasibility and translation of innovative cell therapies, based on PSCs, is actively studied. In general, cell therapy is the transfer of cells into a patient to heal lesions or cure a disease, which cannot be addressed adequately by existing pharmaceutical interventions. For this purpose, cells may originate either from the patient (autologous cells) or a donor (allogeneic or heterogenic cells). The cells used in cell therapy should have the capability to proliferate *in vitro*, and to differentiate into specific cell types in a patient. In the last few years, PSCs have received considerable attention for innovative cell therapies, and has resulted in significant progress in the understanding of their characteristics and therapeutic potential in different lineages. PSCs are considered ideal candidates for cell therapy to achieve tissue repair, or to restore and replace diseased cells.

Using PSCs a large number of animal models has already been treated for numerous diseases to assess the effectiveness of innovative cell-therapies[174-176]. The use of ES cells in cell-therapies is limited due to difficulties in patient-specific derivation, immune-rejection and ethical considerations, whereas derivation of iPS cells has overcome these concerns. Before the clinical application of iPS cell-based therapies is approved, they should be properly assessed using appropriate simulated animal models. Traditionally, laboratory animals (rodents) are used as models due to available knock-out or knock-in gene mutants which demonstrate disease phenotypes. Rodent models for cell-therapies do not always accurately mimic the genetically heterogeneous human situation[177,178]. The use of large animal models seems to be more suitable to analyze efficacies and risks in longitudinal pre-clinical tests and regenerative studies using cell-based-therapy[78,179,180]. Large animal models more closely match human patients in terms of life-span, metabolism, physiology, pathophysiology and biomechanics[181-184]. Large animal models will also permit determination of the effective cell dose, to track the fate of transplanted cells, and to assess their functional integration in the host organ[185]. In addition, large animal models also offer comparative models for research due to naturally occurring diseases, such as cancer[186,187]**.**

Among livestock, the pig is considered a suitable animal model for pre-clinical evaluation of the efficacy and safety of novel cell therapies[179,188,189]. For example, porcine iPS cells can be differentiated *in vitro* into cells of the rod photoreceptor lineage, which were capable of integration into the retina, and generated outer segment-like projections[186,190]. Similarly, improvement of cardiac functions was documented in pig, but also in sheep, dog and rabbit models by assessing the efficacy of cell transplantations. The transplanted cells include skeletal myoblasts, bone marrow cells, cardiac stem cells, and endothelial stem cells[191-193]. Porcine models have also been used for the transplantation of human iPS cell-derived cardiovascular cells for the treatment of acute myocardial infarction, in which improvements were observed in myocardial wall stress, and contractile performance[194]. In addition, porcine iPS cell–derived endothelial cells were transplanted into a murine myocardial infarction model; the results showed an improved myocardial function by paracrine activation[195]. van der Spoel *et al*[196] analyzed the published reports of pre-clinical studies involving large animals for ischemic heart disease cell therapies and they concluded that large animal models allow prediction of the outcome of clinical trials for efficacy and safety. Hence, large animal models are useful targets for assessing the potential of iPS cell therapies to treat diseases, which are caused by the degeneration of specific cell populations, such as Alzheimer’s disease, Huntington´s disease (HD), spinal muscular atrophy, retinitis pigmentosa, and diabetes[80,186]**.**

It is well established that PSCs (including ES cells and iPS cells) are able to differentiate into any cell type *in vivo* or *in vitro* under suitable conditions, whereas the differentiation and reprogramming potentials of some adult stem cells are still under investigation[197]. This indicates that cells have the potential to switch from one cell type to another under the expression of some pluripotent related genes. Recently, progress made in cellular reprogramming and transdifferentiation suggests that it will be possible to generate cells from autologous sources without immunologic rejection and ethical consideration for therapeutic and regeneration purposes[197].

***Conservation of valuable and endangered breeds***

The objective of animal conservation is to maintain biodiversity because elimination of even a single species can interfere with the functioning of an ecosystem[198,199]. The protection of viable populations in their natural habitat (*in situ*) is one of the best methods for biodiversity conservation. *In situ* conservation allows the propagation of a small population using multidisciplinary approaches including genetic and ecological characterizations, but is sometimes insufficient for maintaining adequate genetic diversity[200]. Ex situ conservation approaches have been adopted with the aim of establishing viable populations through cryopreservation of animal genetic resources such as sperm, oocytes, somatic cells, and tissues of valuable domestic breeds and for conservation of endangered wild species. Earlier efforts in wildlife cryo-conservation were generally focused on spermatozoa and embryos[201,202]. More recently, somatic cell bio-banking has emerged as an attractive option for cryo-conservation of endangered and valuable farm animal breeds aiming to revive those in the future using assisted reproduction technologies[203-205]. Advancements made in nuclear transfer and stem cell technologies, and the ability to reprogram differentiated somatic cells into embryonic or germ cell lineages prompted the interest in storing somatic cells for offspring production in future[206-208]. Further advancements in cryobiology may make it possible to cryopreserve different types of cells including somatic cells. Among somatic cells, fibroblast cells are preferable due to abundant availability in skin-tissue and easy establishment in cell culture[203,205]. Primary fibroblast cells derived from livestock such as cattle, buffalo, sheep, goat, and pig have been successfully cryopreserved and are being used for various purposes, including SCNT[205,209-212].

However, the efficiency rates of SCNT in many domestic and wild animals are low, and cloning experiments present a bottleneck in this approach. In mouse cloning, the use of pluripotent blastomeres as donor cells has significantly improved cloning efficiency and decreased the incidence of developmental abnormalities[213]. For endangered species, the availability of oocytes and embryos is often restricted, whereas the generation of iPS cells from somatic cells offers a more practical source of stem cells with less moral and ethical restrictions[214]. The morphology of iPS cells from wild and valuable domestic animals resemble those of ES cells[74,215]. The derivation of iPS cells from skin fibroblasts of endangered primate, silver-maned drill and white rhinoceros[74], snow leopard[215], orangutan[216] and endangered felids such as Bengal tiger, serval and jaguar[217], indicate the feasibility of derivation of iPS cells from threatened species. The generated iPS cells could be expanded for banking as a genetic resource, or used in the animal cloning process to produce viable offspring. Alternatively, iPS cells could be differentiated to derive mature and functional oocytes and spermatozoa, which might be used for *in vitro* fertilization to produce offspring. Furthermore, the availability of iPS cells from diverse species would help to accelerate research progress on evaluating phylogeographic structure, paternity determination, delineating subspecies, assessing gene flow and genetic variation related information, which could be critical for decision-making in managing both *ex situ* and *in situ* wildlife populations[218]. More recently, Hildebrandt *et al*[219] successfully generated ES cells and embryos from the critically endangered northern white rhinoceros. These achievements strengthen the beliefs that modern biotechnologies or iPS cell techniques in collaboration with cloning technology will allow the generation of more offspring from selected parents to ensure genetic diversity and may reduce the interval between generations. In future, the advancements of reproductive techniques and the new knowledge can only be employed when cryopreserved raw biomaterials (germ cells/somatic cells) are maintained, otherwise these would be lost forever[214].

**PSC**s **FROM LIVESTOCK FOR HUMAN HEALTH**

***Drug testing and disease modelling***

Human medicine requires animal models to test any new drug, as *in vitro* systems are still not able to model the pathophysiology of a whole organism. However, many preclinical studies of new therapies conducted on rodents and non-human primates failed due to the fact that they do not allow the prediction of safety and effectiveness in human patients[178,186]. For example, rodent models fail to simulate the basic physiological functions of heart diseases due to their faster heart rate. In contrast, large animals are more similar to humans with regard to their life span, physiology, metabolism, and pathophysiology[179,181,183,220]. The generation of PSCs from livestock[45,58,98] is economically valuable and critically important for the establishment of disease models, testing of new drugs and for the production of medically useful substances such as enzymes and growth hormones[221]. Additionally, animal disease models and animal iPS cells allow the establishment of informative assays to test the efficacy of new compounds, their toxicity, and dosing[222].

Previously, it was demonstrated that iPS cells can be differentiated into lineages of cardiomyocytes and hepatocytes, which were used for disease modelling and drug screening[223-225]. Presently, several biotechnological tools are available to generate disease models using either ES cells or iPS cells, creating new possibilities for their use in drug testing[226,227]. In many cases, somatic cells are also exploited for drug testing and validation, thus promoting new drug discoveries. In addition, the validation of existing drugs in new iPS cell models is performed. The availability of patient-specific iPS cells is crucial to discover new personalized therapeutics.

Large animals such as the domesticated pig have been recognized to be important models for studying colorectal cancer, cardiovascular diseases, cystic fibrosis, diabetes, osteosarcoma, Duchenne muscular dystrophy and Alzheimer’s disease[228]. Similarly, cattle have become a relevant model for studying human female fertility *vis-a-vis* the effects of ageing on fertility[229], uterine infection[230], and ovarian function[231]. In addition, dogs have natural occurring genetic diseases such as hemophilia B[232]. For other diseases that do not occur spontaneously in animals, transgenic animals have been generated such as monkeys with HD and cystic fibrosis-diseased pigs[233]. Induced PS cells generated from HD monkeys were differentiated into neuronal cells *in vitro,* and showed typical HD-like features; thus, representing an attractive model for investigating HD pathogenesis and therapy[234,235]. Recently, CRISPR-Cas9 was used to generate large animal models of neurodegenerative diseases that can more realistically mimic human disease progression[236]. The derivation of iPS cells from patients with congenital heart disease, and differentiation of these cells into cardiomyocytes has been anticipated to serve as a model system to study disease pathogenesis and for drug discovery[225,237].

***Chimera formation and growth of human organs in livestock***

A chimera is a composite organism that is composed of at least two genetically different cell populations[238,239]. It can be produced by combining blastomeres from a minimum of two individual embryos, by aggregating two or more sectioned embryos, or by injecting PSC cells into a blastocyst[240]. Tarkowski *et al*[241] were the first to demonstrate that the aggregation of two sectioned mouse embryos after transfer into the uterus of a surrogate could result in the development of healthy and fertile chimeric animals. If the cells used for chimera generation have differentiation potency they can contribute to form chimera and chimerism rates depend on the potency of the cells. Presently, ES and iPS cells are preferred for aggregation or injection into early embryos due to their pluripotency and ability to contribute to multiple organs of the resulting chimera[5,242-244].

Concurrently, scarcity and demand for human organ donors have motivated scientists to examine options other than donation from deceased patients, such as the possibility of growing human organs in animals. The availability of human PSCs suggested the possibility of producing human organs in animals *via* the chimera route (Figure 4). As proof of principle it was demonstrated that the combination of mouse/rat cells resulted in viable chimeras, with the possibility to direct the one cell type into an organ-specific lineage. To achieve this one species carries a defective gene (Pdx1) necessary for pancreas development. By complementing the cells with the defective Pdx1 gene, with fully competent PSCs from the other rodent species, a chimera with a functional pancreas may develop. A pancreas formed from rat PSCs has been observed in a mouse host, and a pancreas formed from mouse PSCs in a rat host[242,244]. Interestingly, a rat-sized pancreas formed from mouse PSCs, suggested that it could be possible to produce human organs (xenogeneic in nature) in various animal species[244].

Earlier, rat-mouse[242], human-mouse[245], and sheep-goat[246] chimeras were documented. However, blastocyst injection has failed to introduce stem cells into primate embryos[247]. Aggregation of rat-mouse[248], sheep-goat[249], and cattle-buffalo[250] embryos were able to form interspecies chimeras. In spite of the lower survival rate of chimeric embryos produced by the aggregation method compared with blastocyst injection, the chimerism rates have been observed to be higher[251]. Considering the higher rates of chimerism, the human-animal chimeras could be an organ resource, aggregation is also a desirable choice when the embryo and stem cells are in a good growth condition.

The generation of human organs in animal models would have a significant impact in the field of regenerative medicine, since the shortage of donor organs is a major bottleneck. For the generation of human organs, human PSCs would be injected into blastocysts acquired from carrier animals that should be genetically modified to block the development of a particular organ (Figure 4). Thus, only human cells might predominantly contribute to the development of that organ[76]. Previously, human iPS cells were employed to created chimeras upon integration in porcine and bovine blastocysts[5,244]; however, with very limited colonization of early fetuses by the human cells. Yang created human-mouse chimeras overexpressing functional human coagulation factor IX that could be a suitable candidate for hemophilia B treatment[252]. The feasibility of growing complete human organs using a chimeric approach and the proposed immune tolerance (if autologous donor cells are used) still needs to be substantiated.

More recently, the advent of precision genome editing tools like CRISPR/Cas9, efficiently generating the mutation that leads to organ deficiencies in larger animal models further widening the possibility to create human-animal chimeras[253]. The CRISPR/Cas9 mediated zygote genome editing, already successfully documented for mouse and larger livestock species[254], will likely be an effective tool for chimera production[5]. These results open up horizons in the field of regenerative and personalized medicine, but also impose big challenges of ethical concern with low efficiency of human-animal chimeras. Debate on existing frameworks for the ethical assessment of chimeric animal research involving human tissue and their risk minimization has been documented[255,256]. In general, human-animal chimeras might be developed into a strategy to overcome organ shortage, but also a model for studies on organ development; pathogenesis, immunologic defenses, drug screening and toxicity testing. However, this requires us to overcome species-specific incompatibilities, such as differences in placental structures, cell cycle, and growth factor dependencies.

**PSC**s **FROM LIVESTOCK FOR *IN VITRO* MEAT PRODUCTION**

The production of meat *in vitro* using livestock PSCs is proposed as a clean and prominent alternative to slaughtering animals[257]. Bovine stem cells were used to make the world’s first burger from *in vitro* meat, which was served during a London press conference held in 2013[258]. This event was proclaimed as beneficial to reduce the global burden of the livestock industry, and was associated with environmental, ethical, and human health impacts[221,259]. The production of high-quality meat depends on the types of stem cells; source of ingredients and its composition. Among these, myoblast or satellite cells, and recently iPS cells are most important[260]. More recently, cattle umbilical cord blood cells have been reprogrammed to generated iPS cells, subsequently differentiated into muscle and fat cells[214,261]. Recent advancements have been made in the generation of stable bovine[145,262] and porcine PSCs[98], which could potentially be differentiated into skeletal muscle[263,264]. These PSCs form a cell bank with an unaltered and stable karyotype, and may eliminate further dependence on animals for cell isolation. However, this technology is in its infancy, and facing a number of challenges, such as whether *in vitro* meat will have the same taste as real meat, and whether this technology will be able to produce sufficient quantities in a cost-effective and clean way[265-267].

**CONCLUSION**

***Challenges and perspectives***

The PSCs comprise of ES cells derived from embryos and iPS cells obtained from reprogramming of somatic cells. The derivation of ES cells from embryos of livestock such as cattle, buffalo, sheep, goat, pig, horse, cat and dog had a relatively long and until recently unfruitful history. By contrast, the successful generation of iPS cells from livestock species is more promising and a straightforward technology. Commonly, the use of reprogramming vectors that integrate into the host cell genome, and are continuously expressed is a major bottleneck in the utility of iPS cells. To evade this hurdle, the use of non-integrating viral- and non-viral approaches for iPS cells generation resulted into safe and clinical grade cells for further downstream applications[82,268]. Various technical hurdles remain to be overcome for iPS cell technology to fully expand its potential, but remarkable achievements in recent years have led to clinical applications, provided new ways for the development of disease models*,* and improved patients’ treatments in a more adequate and personalized manner[269]. Looking ahead, the results of on-going clinical trials of iPS cells will deliver valuable information for preparing future strategies for cell-based therapy, drug testing, organ generation and disease modelling[237,270]. Pre-clinical testing of these approaches with livestock PSCs and large animal models are crucial for achieving these aims and successful translation into clinical therapies.

In future, PSCs along with novel upcoming technologies will synergically transform cellular reprogramming, differentiation and banking, which is necessarily connected to the industrialization of processes. More recently, massive progress has been achieved by the latest technologies in which ex-vivo and *in vivo* gene editing allowed efficient removal of the gene(s) responsible for the development of particular organs and the creation of new chimeric organs[271]. These approaches have the potential to innovate the field, but issues of safety and ethics need to be addressed in bringing the application of PSCs from bench to bedside.

**REFERENCES**

1 **Banaszynski LA**, Allis CD, Lewis PW. Histone variants in metazoan development. *Dev Cell* 2010; **19**: 662-674 [PMID: 21074717 DOI: 10.1016/j.devcel.2010.10.014]

2 **Evans MJ**, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. *Nature* 1981; **292**: 154-156 [PMID: 7242681 DOI: 10.1038/292154a0]

3 **Martin GR**. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci U S A* 1981; **78**: 7634-7638 [PMID: 6950406 DOI: 10.1073/pnas.78.12.7634]

4 **Nishikawa S**, Jakt LM, Era T. Embryonic stem-cell culture as a tool for developmental cell biology. *Nat Rev Mol Cell Biol* 2007; **8**: 502-507 [PMID: 17522593 DOI: 10.1038/nrm2189]

5 **Wu J**, Platero-Luengo A, Sakurai M, Sugawara A, Gil MA, Yamauchi T, Suzuki K, Bogliotti YS, Cuello C, Morales Valencia M, Okumura D, Luo J, Vilariño M, Parrilla I, Soto DA, Martinez CA, Hishida T, Sánchez-Bautista S, Martinez-Martinez ML, Wang H, Nohalez A, Aizawa E, Martinez-Redondo P, Ocampo A, Reddy P, Roca J, Maga EA, Esteban CR, Berggren WT, Nuñez Delicado E, Lajara J, Guillen I, Guillen P, Campistol JM, Martinez EA, Ross PJ, Izpisua Belmonte JC. Interspecies Chimerism with Mammalian Pluripotent Stem Cells. *Cell* 2017; **168**: 473-486.e15 [PMID: 28129541 DOI: 10.1016/j.cell.2016.12.036]

6 **Evans MJ,** Notarianni E, Laurie S, Moor RM. Derivation and preliminary characterization of pluripotent cell lines from porcine and bovine blastocysts. *Theriogenology* 1990, 33: 125–128 [DOI: 10.1016/0093-691X(90)90603-Q]

7 **Piedrahita JA**, Anderson GB, Bondurant RH. On the isolation of embryonic stem cells: Comparative behavior of murine, porcine and ovine embryos. *Theriogenology* 1990; **34**: 879-901 [PMID: 16726890 DOI: 10.1016/0093-691x(90)90559-c]

8 **Chen LR**, Shiue YL, Bertolini L, Medrano JF, BonDurant RH, Anderson GB. Establishment of pluripotent cell lines from porcine preimplantation embryos. *Theriogenology* 1999; **52**: 195-212 [PMID: 10734388 DOI: 10.1016/S0093-691X(99)00122-3]

9 **Li M**, Zhang D, Hou Y, Jiao L, Zheng X, Wang WH. Isolation and culture of embryonic stem cells from porcine blastocysts. *Mol Reprod Dev* 2003; **65**: 429-434 [PMID: 12840816 DOI: 10.1002/mrd.10301]

10 **First NL**, Sims MM, Park SP, Kent-First MJ. Systems for production of calves from cultured bovine embryonic cells. *Reprod Fertil Dev* 1994; **6**: 553-562 [PMID: 7569033 DOI: 10.1071/rd9940553]

11 **Cibelli JB**, Stice SL, Golueke PJ, Kane JJ, Jerry J, Blackwell C, Ponce de León FA, Robl JM. Transgenic bovine chimeric offspring produced from somatic cell-derived stem-like cells. *Nat Biotechnol* 1998; **16**: 642-646 [PMID: 9661197 DOI: 10.1038/nbt0798-642]

12 **Mitalipova M**, Beyhan Z, First NL. Pluripotency of bovine embryonic cell line derived from precompacting embryos. *Cloning* 2001; **3**: 59-67 [PMID: 11900640 DOI: 10.1089/15204550152475563]

13 **Yadav PS**, Kues WA, Herrmann D, Carnwath JW, Niemann H. Bovine ICM derived cells express the Oct4 ortholog. *Mol Reprod Dev* 2005; **72**: 182-190 [PMID: 15973686 DOI: 10.1002/mrd.20343]

14 **Notarianni E**, Galli C, Laurie S, Moor RM, Evans MJ. Derivation of pluripotent, embryonic cell lines from the pig and sheep. *J Reprod Fertil Suppl* 1991; **43**: 255-260 [PMID: 1843344]

15 **Zhu SX**, Sun Z, Zhang JP. Ovine (Ovis aries) blastula from an in vitro production system and isolation of primary embryonic stem cells. *Zygote* 2007; **15**: 35-41 [PMID: 17391544 DOI: 10.1017/S0967199406003959]

16 **Behboodi E**, Bondareva A, Begin I, Rao K, Neveu N, Pierson JT, Wylie C, Piero FD, Huang YJ, Zeng W, Tanco V, Baldassarre H, Karatzas CN, Dobrinski I. Establishment of goat embryonic stem cells from in vivo produced blastocyst-stage embryos. *Mol Reprod Dev* 2011; **78**: 202-211 [PMID: 21387453 DOI: 10.1002/mrd.21290]

17 **Kumar De A**, Malakar D, Akshey YS, Jena MK, Dutta R. Isolation and characterization of embryonic stem cell-like cells from in vitro produced goat (Capra hircus) embryos. *Anim Biotechnol* 2011; **22**: 181-196 [PMID: 22132812 DOI: 10.1080/10495398.2011.622189]

18 **Saito S**, Ugai H, Sawai K, Yamamoto Y, Minamihashi A, Kurosaka K, Kobayashi Y, Murata T, Obata Y, Yokoyama K. Isolation of embryonic stem-like cells from equine blastocysts and their differentiation in vitro. *FEBS Lett* 2002; **531**: 389-396 [PMID: 12435581 DOI: 10.1016/s0014-5793(02)03550-0]

19 **Anand T**, Kumar D, Singh MK, Shah RA, Chauhan MS, Manik RS, Singla SK, Palta P. Buffalo (Bubalus bubalis) embryonic stem cell-like cells and preimplantation embryos exhibit comparable expression of pluripotency-related antigens. *Reprod Domest Anim* 2011; **46**: 50-58 [PMID: 20042025 DOI: 10.1111/j.1439-0531.2009.01564.x]

20 **Sharma R**, George A, Kamble NM, Singh KP, Chauhan MS, Singla SK, Manik RS, Palta P. Optimization of culture conditions to support long-term self-renewal of buffalo (Bubalus bubalis) embryonic stem cell-like cells. *Cell Reprogram* 2011; **13**: 539-549 [PMID: 22029416 DOI: 10.1089/cell.2011.0041]

21 **Wang L**, Duan E, Sung LY, Jeong BS, Yang X, Tian XC. Generation and characterization of pluripotent stem cells from cloned bovine embryos. *Biol Reprod* 2005; **73**: 149-155 [PMID: 15744021 DOI: 10.1095/biolreprod.104.037150]

22 **Kawase E**, Yamazaki Y, Yagi T, Yanagimachi R, Pedersen RA. Mouse embryonic stem (ES) cell lines established from neuronal cell-derived cloned blastocysts. *Genesis* 2000; **28**: 156-163 [PMID: 11105058]

23 **Munsie MJ**, Michalska AE, O'Brien CM, Trounson AO, Pera MF, Mountford PS. Isolation of pluripotent embryonic stem cells from reprogrammed adult mouse somatic cell nuclei. *Curr Biol* 2000; **10**: 989-992 [PMID: 10985386 DOI: 10.1016/s0960-9822(00)00648-5]

24 **Wakayama S**, Mizutani E, Kishigami S, Thuan NV, Ohta H, Hikichi T, Bui HT, Miyake M, Wakayama T. Mice cloned by nuclear transfer from somatic and ntES cells derived from the same individuals. *J Reprod Dev* 2005; **51**: 765-772 [PMID: 16227673 DOI: 10.1262/jrd.17061]

25 **George A**, Sharma R, Singh KP, Panda SK, Singla SK, Palta P, Manik R, Chauhan MS. Production of cloned and transgenic embryos using buffalo (Bubalus bubalis) embryonic stem cell-like cells isolated from in vitro fertilized and cloned blastocysts. *Cell Reprogram* 2011; **13**: 263-272 [PMID: 21548826 DOI: 10.1089/cell.2010.0094]

26 **Byrne JA**, Pedersen DA, Clepper LL, Nelson M, Sanger WG, Gokhale S, Wolf DP, Mitalipov SM. Producing primate embryonic stem cells by somatic cell nuclear transfer. *Nature* 2007; **450**: 497-502 [PMID: 18004281 DOI: 10.1038/nature06357]

27 **Wells DN**, Oback B, Laible G. Cloning livestock: a return to embryonic cells. *Trends Biotechnol* 2003; **21**: 428-432 [PMID: 14512228 DOI: 10.1016/S0167-7799(03)00206-3]

28 **Kaufman MH**, Robertson EJ, Handyside AH, Evans MJ. Establishment of pluripotential cell lines from haploid mouse embryos. *J Embryol Exp Morphol* 1983; **73**: 249-261 [PMID: 6875460]

29 **Wheeler MB**. Development and validation of swine embryonic stem cells: a review. *Reprod Fertil Dev* 1994; **6**: 563-568 [PMID: 7569034 DOI: 10.1071/rd9940563]

30 Strelchenko N. Bovine pluripotent stem cells. Theriogenology 1996; 45: 131–140 [DOI: 10.1016/0093-691X(95)00362-C]

31 **Sritanaudomchai H**, Pavasuthipaisit K, Kitiyanant Y, Kupradinun P, Mitalipov S, Kusamran T. Characterization and multilineage differentiation of embryonic stem cells derived from a buffalo parthenogenetic embryo. *Mol Reprod Dev* 2007; **74**: 1295-1302 [PMID: 17290421 DOI: 10.1002/mrd.20592]

32 **Muzaffar M**, Selokar NL, Singh KP, Zandi M, Singh MK, Shah RA, Chauhan MS, Singla SK, Palta P, Manik R. Equivalency of buffalo (Bubalus bubalis) embryonic stem cells derived from fertilized, parthenogenetic, and hand-made cloned embryos. *Cell Reprogram* 2012; **14**: 267-279 [PMID: 22582863 DOI: 10.1089/cell.2011.0090]

33 **Singh KP**, Kaushik R, Garg V, Sharma R, George A, Singh MK, Manik RS, Palta P, Singla SK, Chauhan MS. Expression pattern of pluripotent markers in different embryonic developmental stages of buffalo (Bubalus bubalis) embryos and putative embryonic stem cells generated by parthenogenetic activation. *Cell Reprogram* 2012; **14**: 530-538 [PMID: 23194456 DOI: 10.1089/cell.2012.0032]

34 **Muñoz M**, Rodríguez A, De Frutos C, Caamaño JN, Díez C, Facal N, Gómez E. Conventional pluripotency markers are unspecific for bovine embryonic-derived cell-lines. *Theriogenology* 2008; **69**: 1159-1164 [PMID: 18420262 DOI: 10.1016/j.theriogenology.2008.02.014]

35 **Brevini TA**, Pennarossa G, Gandolfi F. No shortcuts to pig embryonic stem cells. *Theriogenology* 2010; **74**: 544-550 [PMID: 20570327 DOI: 10.1016/j.theriogenology.2010.04.020]

36 **Nowak-Imialek M**, Kues W, Carnwath JW, Niemann H. Pluripotent stem cells and reprogrammed cells in farm animals. *Microsc Microanal* 2011; **17**: 474-497 [PMID: 21682936 DOI: 10.1017/S1431927611000080]

37 **Li P**, Tong C, Mehrian-Shai R, Jia L, Wu N, Yan Y, Maxson RE, Schulze EN, Song H, Hsieh CL, Pera MF, Ying QL. Germline competent embryonic stem cells derived from rat blastocysts. *Cell* 2008; **135**: 1299-1310 [PMID: 19109898 DOI: 10.1016/j.cell.2008.12.006]

38 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]

39 **Okita K**, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. *Nature* 2007; **448**: 313-317 [PMID: 17554338 DOI: 10.1038/nature05934]

40 **Takahashi K**, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007; **131**: 861-872 [PMID: 18035408 DOI: 10.1016/j.cell.2007.11.019]

41 **Park ET**, Gum JR, Kakar S, Kwon SW, Deng G, Kim YS. Aberrant expression of SOX2 upregulates MUC5AC gastric foveolar mucin in mucinous cancers of the colorectum and related lesions. *Int J Cancer* 2008; **122**: 1253-1260 [PMID: 18027866 DOI: 10.1002/ijc.23225]

42 **Esteban MA**, Xu J, Yang J, Peng M, Qin D, Li W, Jiang Z, Chen J, Deng K, Zhong M, Cai J, Lai L, Pei D. Generation of induced pluripotent stem cell lines from Tibetan miniature pig. *J Biol Chem* 2009; **284**: 17634-17640 [PMID: 19376775 DOI: 10.1074/jbc.M109.008938]

43 **Ezashi T**, Telugu BP, Alexenko AP, Sachdev S, Sinha S, Roberts RM. Derivation of induced pluripotent stem cells from pig somatic cells. *Proc Natl Acad Sci U S A* 2009; **106**: 10993-10998 [PMID: 19541600 DOI: 10.1073/pnas.0905284106]

44 **Wu Z**, Chen J, Ren J, Bao L, Liao J, Cui C, Rao L, Li H, Gu Y, Dai H, Zhu H, Teng X, Cheng L, Xiao L. Generation of pig induced pluripotent stem cells with a drug-inducible system. *J Mol Cell Biol* 2009; **1**: 46-54 [PMID: 19502222 DOI: 10.1093/jmcb/mjp003]

45 **West FD**, Terlouw SL, Kwon DJ, Mumaw JL, Dhara SK, Hasneen K, Dobrinsky JR, Stice SL. Porcine induced pluripotent stem cells produce chimeric offspring. *Stem Cells Dev* 2010; **19**: 1211-1220 [PMID: 20380514 DOI: 10.1089/scd.2009.0458]

46 **Montserrat N**, Bahima EG, Batlle L, Häfner S, Rodrigues AM, González F, Izpisúa Belmonte JC. Generation of pig iPS cells: a model for cell therapy. *J Cardiovasc Transl Res* 2011; **4**: 121-130 [PMID: 21088946 DOI: 10.1007/s12265-010-9233-3]

47 **Kues WA**, Herrmann D, Barg-Kues B, Haridoss S, Nowak-Imialek M, Buchholz T, Streeck M, Grebe A, Grabundzija I, Merkert S, Martin U, Hall VJ, Rasmussen MA, Ivics Z, Hyttel P, Niemann H. Derivation and characterization of sleeping beauty transposon-mediated porcine induced pluripotent stem cells. *Stem Cells Dev* 2013; **22**: 124-135 [PMID: 22989381 DOI: 10.1089/scd.2012.0382]

48 **Bao L**, He L, Chen J, Wu Z, Liao J, Rao L, Ren J, Li H, Zhu H, Qian L, Gu Y, Dai H, Xu X, Zhou J, Wang W, Cui C, Xiao L. Reprogramming of ovine adult fibroblasts to pluripotency via drug-inducible expression of defined factors. *Cell Res* 2011; **21**: 600-608 [PMID: 21221129 DOI: 10.1038/cr.2011.6]

49 **Li Y**, Cang M, Lee AS, Zhang K, Liu D. Reprogramming of sheep fibroblasts into pluripotency under a drug-inducible expression of mouse-derived defined factors. *PLoS One* 2011; **6**: e15947 [PMID: 21253598 DOI: 10.1371/journal.pone.0015947]

50 **Liu J**, Balehosur D, Murray B, Kelly JM, Sumer H, Verma PJ. Generation and characterization of reprogrammed sheep induced pluripotent stem cells. *Theriogenology* 2012; **77**: 338-46.e1 [PMID: 21958637 DOI: 10.1016/j.theriogenology.2011.08.006]

51 **Ren J**, Pak Y, He L, Qian L, Gu Y, Li H, Rao L, Liao J, Cui C, Xu X, Zhou J, Ri H, Xiao L. Generation of hircine-induced pluripotent stem cells by somatic cell reprogramming. *Cell Res* 2011; **21**: 849-853 [PMID: 21403680 DOI: 10.1038/cr.2011.37]

52 **Song H**, Li H, Huang M, Xu D, Gu C, Wang Z, Dong F, Wang F. Induced pluripotent stem cells from goat fibroblasts. *Mol Reprod Dev* 2013; **80**: 1009-1017 [PMID: 24123501 DOI: 10.1002/mrd.22266]

53 **Shimada H**, Nakada A, Hashimoto Y, Shigeno K, Shionoya Y, Nakamura T. Generation of canine induced pluripotent stem cells by retroviral transduction and chemical inhibitors. *Mol Reprod Dev* 2010; **77**: 2 [PMID: 19890968 DOI: 10.1002/mrd.21117]

54 **Luo J**, Suhr ST, Chang EA, Wang K, Ross PJ, Nelson LL, Venta PJ, Knott JG, Cibelli JB. Generation of leukemia inhibitory factor and basic fibroblast growth factor-dependent induced pluripotent stem cells from canine adult somatic cells. *Stem Cells Dev* 2011; **20**: 1669-1678 [PMID: 21495906 DOI: 10.1089/scd.2011.0127]

55 **Whitworth DJ**, Ovchinnikov DA, Wolvetang EJ. Generation and characterization of LIF-dependent canine induced pluripotent stem cells from adult dermal fibroblasts. *Stem Cells Dev* 2012; **21**: 2288-2297 [PMID: 22221227 DOI: 10.1089/scd.2011.0608]

56 **Koh S**, Thomas R, Tsai S, Bischoff S, Lim JH, Breen M, Olby NJ, Piedrahita JA. Growth requirements and chromosomal instability of induced pluripotent stem cells generated from adult canine fibroblasts. *Stem Cells Dev* 2013; **22**: 951-963 [PMID: 23016947 DOI: 10.1089/scd.2012.0393]

57 **Sumer H**, Liu J, Malaver-Ortega LF, Lim ML, Khodadadi K, Verma PJ. NANOG is a key factor for induction of pluripotency in bovine adult fibroblasts. *J Anim Sci* 2011; **89**: 2708-2716 [PMID: 21478453 DOI: 10.2527/jas.2010-3666]

58 **Talluri TR**, Kumar D, Glage S, Garrels W, Ivics Z, Debowski K, Behr R, Niemann H, Kues WA. Derivation and characterization of bovine induced pluripotent stem cells by transposon-mediated reprogramming. *Cell Reprogram* 2015; **17**: 131-140 [PMID: 25826726 DOI: 10.1089/cell.2014.0080]

59 **Nagy K**, Sung HK, Zhang P, Laflamme S, Vincent P, Agha-Mohammadi S, Woltjen K, Monetti C, Michael IP, Smith LC, Nagy A. Induced pluripotent stem cell lines derived from equine fibroblasts. *Stem Cell Rev Rep* 2011; **7**: 693-702 [PMID: 21347602 DOI: 10.1007/s12015-011-9239-5]

60 **Hackett CH**, Greve L, Novakofski KD, Fortier LA. Comparison of gene-specific DNA methylation patterns in equine induced pluripotent stem cell lines with cells derived from equine adult and fetal tissues. *Stem Cells Dev* 2012; **21**: 1803-1811 [PMID: 21988203 DOI: 10.1089/scd.2011.0055]

61 **Breton A**, Sharma R, Diaz AC, Parham AG, Graham A, Neil C, Whitelaw CB, Milne E, Donadeu FX. Derivation and characterization of induced pluripotent stem cells from equine fibroblasts. *Stem Cells Dev* 2013; **22**: 611-621 [PMID: 22897112 DOI: 10.1089/scd.2012.0052]

62 **Donadeu FX**. Equine induced pluripotent stem cells or how to turn skin cells into neurons: horse tissues a la carte? *Equine Vet J* 2014; **46**: 534-537 [PMID: 25099189 DOI: 10.1111/evj.12300]

63 **Whitworth DJ**, Ovchinnikov DA, Sun J, Fortuna PR, Wolvetang EJ. Generation and characterization of leukemia inhibitory factor-dependent equine induced pluripotent stem cells from adult dermal fibroblasts. *Stem Cells Dev* 2014; **23**: 1515-1523 [PMID: 24555755 DOI: 10.1089/scd.2013.0461]

64 **Sharma R**, Livesey MR, Wyllie DJ, Proudfoot C, Whitelaw CB, Hay DC, Donadeu FX. Generation of functional neurons from feeder-free, keratinocyte-derived equine induced pluripotent stem cells. *Stem Cells Dev* 2014; **23**: 1524-1534 [PMID: 24548115 DOI: 10.1089/scd.2013.0565]

65 **Deng Y**, Liu Q, Luo C, Chen S, Li X, Wang C, Liu Z, Lei X, Zhang H, Sun H, Lu F, Jiang J, Shi D. Generation of induced pluripotent stem cells from buffalo (Bubalus bubalis) fetal fibroblasts with buffalo defined factors. *Stem Cells Dev* 2012; **21**: 2485-2494 [PMID: 22420535 DOI: 10.1089/scd.2012.0018]

66 **Kumar D**, Anand T, Vijayalakshmy K, Sharma P, Rajendran R, Selokar NL, Yadav PS, Kumar D. Transposon mediated reprogramming of buffalo fetal fibroblasts to induced pluripotent stem cells in feeder free culture conditions. *Res Vet Sci* 2019; **123**: 252-260 [PMID: 30703616 DOI: 10.1016/j.rvsc.2019.01.015]

67 **Sartori C**, DiDomenico AI, Thomson AJ, Milne E, Lillico SG, Burdon TG, Whitelaw CB. Ovine-induced pluripotent stem cells can contribute to chimeric lambs. *Cell Reprogram* 2012; **14**: 8-19 [PMID: 22217199 DOI: 10.1089/cell.2011.0050]

68 **Kanatsu-Shinohara M**, Inoue K, Lee J, Yoshimoto M, Ogonuki N, Miki H, Baba S, Kato T, Kazuki Y, Toyokuni S, Toyoshima M, Niwa O, Oshimura M, Heike T, Nakahata T, Ishino F, Ogura A, Shinohara T. Generation of pluripotent stem cells from neonatal mouse testis. *Cell* 2004; **119**: 1001-1012 [PMID: 15620358 DOI: 10.1016/j.cell.2004.11.011]

69 **Guan K**, Nayernia K, Maier LS, Wagner S, Dressel R, Lee JH, Nolte J, Wolf F, Li M, Engel W, Hasenfuss G. Pluripotency of spermatogonial stem cells from adult mouse testis. *Nature* 2006; **440**: 1199-1203 [PMID: 16565704 DOI: 10.1038/nature04697]

70 **Lee SW**, Wu G, Choi NY, Lee HJ, Bang JS, Lee Y, Lee M, Ko K, Schöler HR, Ko K. Self-Reprogramming of Spermatogonial Stem Cells into Pluripotent Stem Cells without Microenvironment of Feeder Cells. *Mol Cells* 2018; **41**: 631-638 [PMID: 29991673 DOI: 10.14348/molcells.2018.2294]

71 **Ko K**, Tapia N, Wu G, Kim JB, Bravo MJ, Sasse P, Glaser T, Ruau D, Han DW, Greber B, Hausdörfer K, Sebastiano V, Stehling M, Fleischmann BK, Brüstle O, Zenke M, Schöler HR. Induction of pluripotency in adult unipotent germline stem cells. *Cell Stem Cell* 2009; **5**: 87-96 [PMID: 19570517 DOI: 10.1016/j.stem.2009.05.025]

72 **Wang H**, Jiang M, Bi H, Chen X, He L, Li X, Wu J. Conversion of female germline stem cells from neonatal and prepubertal mice into pluripotent stem cells. *J Mol Cell Biol* 2014; **6**: 164-171 [PMID: 24755856 DOI: 10.1093/jmcb/mju004]

73 **Zeng F**, Huang F, Guo J, Hu X, Liu C, Wang H. Emerging methods to generate artificial germ cells from stem cells. *Biol Reprod* 2015; **92**: 89 [PMID: 25715792 DOI: 10.1095/biolreprod.114.124800]

74 **Ben-Nun IF**, Montague SC, Houck ML, Tran HT, Garitaonandia I, Leonardo TR, Wang YC, Charter SJ, Laurent LC, Ryder OA, Loring JF. Induced pluripotent stem cells from highly endangered species. *Nat Methods* 2011; **8**: 829-831 [PMID: 21892153 DOI: 10.1038/nmeth.1706]

75 **Schmidt R**, Plath K. The roles of the reprogramming factors Oct4, Sox2 and Klf4 in resetting the somatic cell epigenome during induced pluripotent stem cell generation. *Genome Biol* 2012; **13**: 251 [PMID: 23088445 DOI: 10.1186/gb-2012-13-10-251]

76 **Rashid T**, Kobayashi T, Nakauchi H. Revisiting the flight of Icarus: making human organs from PSCs with large animal chimeras. *Cell Stem Cell* 2014; **15**: 406-409 [PMID: 25280216 DOI: 10.1016/j.stem.2014.09.013]

77 **Keefer CL**. Artificial cloning of domestic animals. *Proc Natl Acad Sci U S A* 2015; **112**: 8874-8878 [PMID: 26195770 DOI: 10.1073/pnas.1501718112]

78 **Kumar D**, Talluri TR, Anand T, Kues WA. Induced pluripotent stem cells: Mechanisms, achievements and perspectives in farm animals. *World J Stem Cells* 2015; **7**: 315-328 [PMID: 25815117 DOI: 10.4252/wjsc.v7.i2.315]

79 **Ogorevc J**, Orehek S, Dovč P. Cellular reprogramming in farm animals: an overview of iPSC generation in the mammalian farm animal species. *J Anim Sci Biotechnol* 2016; **7**: 10 [PMID: 26900466 DOI: 10.1186/s40104-016-0070-3]

80 **Kumar D**, Anand T, Kues WA. Clinical potential of human-induced pluripotent stem cells : Perspectives of induced pluripotent stem cells. *Cell Biol Toxicol* 2017; **33**: 99-112 [PMID: 27900567 DOI: 10.1007/s10565-016-9370-9]

81 **Kumar D**, Talluri TR, Anand T, Kues WA. Transposon-based reprogramming to induced pluripotency. *Histol Histopathol* 2015; **30**: 1397-1409 [PMID: 26301418 DOI: 10.14670/HH-11-656]

82 **Haridhasapavalan KK**, Borgohain MP, Dey C, Saha B, Narayan G, Kumar S, Thummer RP. An insight into non-integrative gene delivery approaches to generate transgene-free induced pluripotent stem cells. *Gene* 2019; **686**: 146-159 [PMID: 30472380 DOI: 10.1016/j.gene.2018.11.069]

83 **Kumar D**, Anand T, Talluri TR, Kues WA. Potential of transposon-mediated cellular reprogramming towards cell-based therapies. *World J Stem Cells* 2020; **12**: 527-544 [PMID: 32843912 DOI: 10.4252/wjsc.v12.i7.527]

84 **Koh S**, Piedrahita JA. From "ES-like" cells to induced pluripotent stem cells: a historical perspective in domestic animals. *Theriogenology* 2014; **81**: 103-111 [PMID: 24274415 DOI: 10.1016/j.theriogenology.2013.09.009]

85 **Ezashi T**, Yuan Y, Roberts RM. Pluripotent Stem Cells from Domesticated Mammals. *Annu Rev Anim Biosci* 2016; **4**: 223-253 [PMID: 26566158 DOI: 10.1146/annurev-animal-021815-111202]

86 **Coucouvanis E**, Martin GR. BMP signaling plays a role in visceral endoderm differentiation and cavitation in the early mouse embryo. *Development* 1999; **126**: 535-546 [PMID: 9876182]

87 **Muñoz M**, Díez C, Caamaño JN, Jouneau A, Hue I, Gómez E. Embryonic stem cells in cattle. *Reprod Domest Anim* 2008; **43 Suppl 4**: 32-37 [PMID: 18803754 DOI: 10.1111/j.1439-0531.2008.01229.x]

88 **Talbot NC**, Blomberg Le Ann. The pursuit of ES cell lines of domesticated ungulates. *Stem Cell Rev* 2008; **4**: 235-254 [PMID: 18612851 DOI: 10.1007/s12015-008-9026-0]

89 **Gandolfi F**, Pennarossa G, Maffei S, Brevini T. Why is it so difficult to derive pluripotent stem cells in domestic ungulates? *Reprod Domest Anim* 2012; **47 Suppl 5**: 11-17 [PMID: 22913556 DOI: 10.1111/j.1439-0531.2012.02106.x]

90 **Maddox-Hyttel P**, Alexopoulos NI, Vajta G, Lewis I, Rogers P, Cann L, Callesen H, Tveden-Nyborg P, Trounson A. Immunohistochemical and ultrastructural characterization of the initial post-hatching development of bovine embryos. *Reproduction* 2003; **125**: 607-623 [PMID: 12683931]

91 **Vejlsted M**, Du Y, Vajta G, Maddox-Hyttel P. Post-hatching development of the porcine and bovine embryo--defining criteria for expected development in vivo and in vitro. *Theriogenology* 2006; **65**: 153-165 [PMID: 16257443 DOI: 10.1016/j.theriogenology.2005.09.021]

92 **Blomberg LA**, Telugu BP. Twenty years of embryonic stem cell research in farm animals. *Reprod Domest Anim* 2012; **47 Suppl 4**: 80-85 [PMID: 22827354 DOI: 10.1111/j.1439-0531.2012.02059.x]

93 **Degrelle SA**, Campion E, Cabau C, Piumi F, Reinaud P, Richard C, Renard JP, Hue I. Molecular evidence for a critical period in mural trophoblast development in bovine blastocysts. *Dev Biol* 2005; **288**: 448-460 [PMID: 16289134 DOI: 10.1016/j.ydbio.2005.09.043]

94 **Rossant J**. Stem cells and lineage development in the mammalian blastocyst. *Reprod Fertil Dev* 2007; **19**: 111-118 [PMID: 17389140 DOI: 10.1071/rd06125]

95 **Gonçalves NN**, Ambrósio CE, Piedrahita JA. Stem cells and regenerative medicine in domestic and companion animals: a multispecies perspective. *Reprod Domest Anim* 2014; **49 Suppl 4**: 2-10 [PMID: 25277427 DOI: 10.1111/rda.12392]

96 **Vassiliev I**, Vassilieva S, Beebe LF, Harrison SJ, McIlfatrick SM, Nottle MB. In vitro and in vivo characterization of putative porcine embryonic stem cells. *Cell Reprogram* 2010; **12**: 223-230 [PMID: 20677936 DOI: 10.1089/cell.2009.0053]

97 **Xue B**, Li Y, He Y, Wei R, Sun R, Yin Z, Bou G, Liu Z. Porcine Pluripotent Stem Cells Derived from IVF Embryos Contribute to Chimeric Development In Vivo. *PLoS One* 2016; **11**: e0151737 [PMID: 26991423 DOI: 10.1371/journal.pone.0151737]

98 **Gao X**, Nowak-Imialek M, Chen X, Chen D, Herrmann D, Ruan D, Chen ACH, Eckersley-Maslin MA, Ahmad S, Lee YL, Kobayashi T, Ryan D, Zhong J, Zhu J, Wu J, Lan G, Petkov S, Yang J, Antunes L, Campos LS, Fu B, Wang S, Yong Y, Wang X, Xue SG, Ge L, Liu Z, Huang Y, Nie T, Li P, Wu D, Pei D, Zhang Y, Lu L, Yang F, Kimber SJ, Reik W, Zou X, Shang Z, Lai L, Surani A, Tam PPL, Ahmed A, Yeung WSB, Teichmann SA, Niemann H, Liu P. Establishment of porcine and human expanded potential stem cells. *Nat Cell Biol* 2019; **21**: 687-699 [PMID: 31160711 DOI: 10.1038/s41556-019-0333-2]

99 **Vaags AK**, Rosic-Kablar S, Gartley CJ, Zheng YZ, Chesney A, Villagómez DA, Kruth SA, Hough MR. Derivation and characterization of canine embryonic stem cell lines with in vitro and in vivo differentiation potential. *Stem Cells* 2009; **27**: 329-340 [PMID: 19038794 DOI: 10.1634/stemcells.2008-0433]

100 **Wang H,** Pei Y, Li N, Han J. Progress, problems and prospects of porcine pluripotent stem cells. *Front Agric Sci Eng* 2014; **1:** 6–15 [DOI: 10.15302/J-FASE-2014009]

101 **Malaver-Ortega LF**, Sumer H, Liu J, Verma PJ. The state of the art for pluripotent stem cells derivation in domestic ungulates. *Theriogenology* 2012; **78**: 1749-1762 [PMID: 22578625 DOI: 10.1016/j.theriogenology.2012.03.031]

102 **Nowak-Imialek M**, Niemann H. Pluripotent cells in farm animals: state of the art and future perspectives. *Reprod Fertil Dev* 2012; **25**: 103-128 [PMID: 23244833 DOI: 10.1071/RD12265]

103 **Navarro M**, Soto DA, Pinzon CA, Wu J, Ross PJ. Livestock pluripotency is finally captured in vitro. *Reprod Fertil Dev* 2019; **32**: 11-39 [PMID: 32188555 DOI: 10.1071/RD19272]

104 **Lu Y**, Mumaw JL, West FD, Stice SL. Livestock induced pluripotent stem cells. *Reprod Domest Anim* 2012; **47 Suppl 4**: 72-76 [PMID: 22827352 DOI: 10.1111/j.1439-0531.2012.02057.x]

105 **West FD**, Uhl EW, Liu Y, Stowe H, Lu Y, Yu P, Gallegos-Cardenas A, Pratt SL, Stice SL. Brief report: chimeric pigs produced from induced pluripotent stem cells demonstrate germline transmission and no evidence of tumor formation in young pigs. *Stem Cells* 2011; **29**: 1640-1643 [PMID: 22039609 DOI: 10.1002/stem.713]

106 **Jaenisch R**, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. *Cell* 2008; **132**: 567-582 [PMID: 18295576 DOI: 10.1016/j.cell.2008.01.015]

107 **Cai J**, Li W, Su H, Qin D, Yang J, Zhu F, Xu J, He W, Guo X, Labuda K, Peterbauer A, Wolbank S, Zhong M, Li Z, Wu W, So KF, Redl H, Zeng L, Esteban MA, Pei D. Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. *J Biol Chem* 2010; **285**: 11227-11234 [PMID: 20139068 DOI: 10.1074/jbc.M109.086389]

108 **Nichols J**, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Schöler H, Smith A. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell* 1998; **95**: 379-391 [PMID: 9814708 DOI: 10.1016/s0092-8674(00)81769-9]

109 **Avilion AA**, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. *Genes Dev* 2003; **17**: 126-140 [PMID: 12514105 DOI: 10.1101/gad.224503]

110 **Hart AH**, Hartley L, Ibrahim M, Robb L. Identification, cloning and expression analysis of the pluripotency promoting Nanog genes in mouse and human. *Dev Dyn* 2004; **230**: 187-198 [PMID: 15108323 DOI: 10.1002/dvdy.20034]

111 **Kim J**, Chu J, Shen X, Wang J, Orkin SH. An extended transcriptional network for pluripotency of embryonic stem cells. *Cell* 2008; **132**: 1049-1061 [PMID: 18358816 DOI: 10.1016/j.cell.2008.02.039]

112 **Kashyap V**, Rezende NC, Scotland KB, Shaffer SM, Persson JL, Gudas LJ, Mongan NP. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. *Stem Cells Dev* 2009; **18**: 1093-1108 [PMID: 19480567 DOI: 10.1089/scd.2009.0113]

113 **Chew JL**, Loh YH, Zhang W, Chen X, Tam WL, Yeap LS, Li P, Ang YS, Lim B, Robson P, Ng HH. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. *Mol Cell Biol* 2005; **25**: 6031-6046 [PMID: 15988017 DOI: 10.1128/MCB.25.14.6031-6046.2005]

114 **Boyer LA**, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, Young RA. Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* 2005; **122**: 947-956 [PMID: 16153702 DOI: 10.1016/j.cell.2005.08.020]

115 **Silva J**, Chambers I, Pollard S, Smith A. Nanog promotes transfer of pluripotency after cell fusion. *Nature* 2006; **441**: 997-1001 [PMID: 16791199 DOI: 10.1038/nature04914]

116 **Hayashi Y**, Caboni L, Das D, Yumoto F, Clayton T, Deller MC, Nguyen P, Farr CL, Chiu HJ, Miller MD, Elsliger MA, Deacon AM, Godzik A, Lesley SA, Tomoda K, Conklin BR, Wilson IA, Yamanaka S, Fletterick RJ. Structure-based discovery of NANOG variant with enhanced properties to promote self-renewal and reprogramming of pluripotent stem cells. *Proc Natl Acad Sci U S A* 2015; **112**: 4666-4671 [PMID: 25825768 DOI: 10.1073/pnas.1502855112]

117 **Kues WA**, Nowak-Imialek M, Haridoss S, Niemann H. Strategies for the derivation of pluripotent cells from farm animals. *Reprod Domest Anim* 2010; **45 Suppl 3**: 25-31 [PMID: 24417196 DOI: 10.1111/j.1439-0531.2010.01663.x]

118 **Han X**, Han J, Ding F, Cao S, Lim SS, Dai Y, Zhang R, Zhang Y, Lim B, Li N. Generation of induced pluripotent stem cells from bovine embryonic fibroblast cells. *Cell Res* 2011; **21**: 1509-1512 [PMID: 21826109 DOI: 10.1038/cr.2011.125]

119 **Cao H**, Yang P, Pu Y, Sun X, Yin H, Zhang Y, Zhang Y, Li Y, Liu Y, Fang F, Zhang Z, Tao Y, Zhang X. Characterization of bovine induced pluripotent stem cells by lentiviral transduction of reprogramming factor fusion proteins. *Int J Biol Sci* 2012; **8**: 498-511 [PMID: 22457605 DOI: 10.7150/ijbs.3723]

120 **Canizo JR**, Vazquez Echegaray C, Klisch D, Aller JF, Paz DA, Alberio RH, Alberio R, Guberman AS. Exogenous human OKSM factors maintain pluripotency gene expression of bovine and porcine iPS-like cells obtained with STEMCCA delivery system. *BMC Res Notes* 2018; **11**: 509 [PMID: 30053877 DOI: 10.1186/s13104-018-3627-8]

121 **German SD**, Campbell KH, Thornton E, McLachlan G, Sweetman D, Alberio R. Ovine induced pluripotent stem cells are resistant to reprogramming after nuclear transfer. *Cell Reprogram* 2015; **17**: 19-27 [PMID: 25513856 DOI: 10.1089/cell.2014.0071]

122 **Dutton LC**, Dudhia J, Guest DJ, Connolly DJ. Inducing Pluripotency in the Domestic Cat (*Felis catus*). *Stem Cells Dev* 2019; **28**: 1299-1309 [PMID: 31389301 DOI: 10.1089/scd.2019.0142]

123 **Zhao T**, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. *Nature* 2011; **474**: 212-215 [PMID: 21572395 DOI: 10.1038/nature10135]

124 **Fusaki N**, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. *Proc Jpn Acad Ser B Phys Biol Sci* 2009; **85**: 348-362 [PMID: 19838014 DOI: 10.2183/pjab.85.348]

125 **Tashiro K**, Inamura M, Kawabata K, Sakurai F, Yamanishi K, Hayakawa T, Mizuguchi H. Efficient adipocyte and osteoblast differentiation from mouse induced pluripotent stem cells by adenoviral transduction. *Stem Cells* 2009; **27**: 1802-1811 [PMID: 19544436 DOI: 10.1002/stem.108]

126 **Chow L**, Johnson V, Regan D, Wheat W, Webb S, Koch P, Dow S. Safety and immune regulatory properties of canine induced pluripotent stem cell-derived mesenchymal stem cells. *Stem Cell Res* 2017; **25**: 221-232 [PMID: 29172152 DOI: 10.1016/j.scr.2017.11.010]

127 **Tsukamoto M**, Nishimura T, Yodoe K, Kanegi R, Tsujimoto Y, Alam ME, Kuramochi M, Kuwamura M, Ohtaka M, Nishimura K, Nakanishi M, Inaba T, Sugiura K, Hatoya S. Generation of Footprint-Free Canine Induced Pluripotent Stem Cells Using Auto-Erasable Sendai Virus Vector. *Stem Cells Dev* 2018; **27**: 1577-1586 [PMID: 30215317 DOI: 10.1089/scd.2018.0084]

128 **Huang B**, Li T, Alonso-Gonzalez L, Gorre R, Keatley S, Green A, Turner P, Kallingappa PK, Verma V, Oback B. A virus-free poly-promoter vector induces pluripotency in quiescent bovine cells under chemically defined conditions of dual kinase inhibition. *PLoS One* 2011; **6**: e24501 [PMID: 21912700 DOI: 10.1371/journal.pone.0024501]

129 **Kawaguchi T**, Tsukiyama T, Kimura K, Matsuyama S, Minami N, Yamada M, Imai H. Generation of Naïve Bovine Induced Pluripotent Stem Cells Using PiggyBac Transposition of Doxycycline-Inducible Transcription Factors. *PLoS One* 2015; **10**: e0135403 [PMID: 26287611 DOI: 10.1371/journal.pone.0135403]

130 **Zhao L**, Wang Z, Zhang J, Yang J, Gao X, Wu B, Zhao G, Bao S, Hu S, Liu P, Li X. Characterization of the single-cell derived bovine induced pluripotent stem cells. *Tissue Cell* 2017; **49**: 521-527 [PMID: 28720304 DOI: 10.1016/j.tice.2017.05.005]

131 **Telugu BP**, Ezashi T, Roberts RM. Porcine induced pluripotent stem cells analogous to naïve and primed embryonic stem cells of the mouse. *Int J Dev Biol* 2010; **54**: 1703-1711 [PMID: 21305472 DOI: 10.1387/ijdb.103200bt]

132 **Li D**, Secher J, Hyttel P, Ivask M, Kolko M, Hall VJ, Freude KK. Generation of transgene-free porcine intermediate type induced pluripotent stem cells. *Cell Cycle* 2018; **17**: 2547-2563 [PMID: 30457474 DOI: 10.1080/15384101.2018.1548790]

133 **Pessôa LVF**, Bressan FF, Freude KK. Induced pluripotent stem cells throughout the animal kingdom: Availability and applications. *World J Stem Cells* 2019; **11**: 491-505 [PMID: 31523369 DOI: 10.4252/wjsc.v11.i8.491]

134 **Goszczynski DE**, Cheng H, Demyda-Peyrás S, Medrano JF, Wu J, Ross PJ. In vitro breeding: application of embryonic stem cells to animal production†. *Biol Reprod* 2019; **100**: 885-895 [PMID: 30551176 DOI: 10.1093/biolre/ioy256]

135 **Ying Y**, Liu XM, Marble A, Lawson KA, Zhao GQ. Requirement of Bmp8b for the generation of primordial germ cells in the mouse. *Mol Endocrinol* 2000; **14**: 1053-1063 [PMID: 10894154 DOI: 10.1210/mend.14.7.0479]

136 **Ying Y**, Zhao GQ. Cooperation of endoderm-derived BMP2 and extraembryonic ectoderm-derived BMP4 in primordial germ cell generation in the mouse. *Dev Biol* 2001; **232**: 484-492 [PMID: 11401407 DOI: 10.1006/dbio.2001.0173]

137 **Ohinata Y**, Ohta H, Shigeta M, Yamanaka K, Wakayama T, Saitou M. A signaling principle for the specification of the germ cell lineage in mice. *Cell* 2009; **137**: 571-584 [PMID: 19410550 DOI: 10.1016/j.cell.2009.03.014]

138 **García-Ruiz A**, Cole JB, VanRaden PM, Wiggans GR, Ruiz-López FJ, Van Tassell CP. Changes in genetic selection differentials and generation intervals in US Holstein dairy cattle as a result of genomic selection. *Proc Natl Acad Sci U S A* 2016; **113**: E3995-E4004 [PMID: 27354521 DOI: 10.1073/pnas.1519061113]

139 **Hou Z**, An L, Han J, Yuan Y, Chen D, Tian J. Revolutionize livestock breeding in the future: an animal embryo-stem cell breeding system in a dish. *J Anim Sci Biotechnol* 2018; **9**: 90 [PMID: 30568797 DOI: 10.1186/s40104-018-0304-7]

140 **Hayashi K**, Ohta H, Kurimoto K, Aramaki S, Saitou M. Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. *Cell* 2011; **146**: 519-532 [PMID: 21820164 DOI: 10.1016/j.cell.2011.06.052]

141 **Hayashi K**, Ogushi S, Kurimoto K, Shimamoto S, Ohta H, Saitou M. Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice. *Science* 2012; **338**: 971-975 [PMID: 23042295 DOI: 10.1126/science.1226889]

142 **Teramura T**, Takehara T, Kawata N, Fujinami N, Mitani T, Takenoshita M, Matsumoto K, Saeki K, Iritani A, Sagawa N, Hosoi Y. Primate embryonic stem cells proceed to early gametogenesis in vitro. *Cloning Stem Cells* 2007; **9**: 144-156 [PMID: 17579549 DOI: 10.1089/clo.2006.0070]

143 **Yamauchi K**, Hasegawa K, Chuma S, Nakatsuji N, Suemori H. In vitro germ cell differentiation from cynomolgus monkey embryonic stem cells. *PLoS One* 2009; **4**: e5338 [PMID: 19399191 DOI: 10.1371/journal.pone.0005338]

144 **Hermann BP**, Sukhwani M, Winkler F, Pascarella JN, Peters KA, Sheng Y, Valli H, Rodriguez M, Ezzelarab M, Dargo G, Peterson K, Masterson K, Ramsey C, Ward T, Lienesch M, Volk A, Cooper DK, Thomson AW, Kiss JE, Penedo MC, Schatten GP, Mitalipov S, Orwig KE. Spermatogonial stem cell transplantation into rhesus testes regenerates spermatogenesis producing functional sperm. *Cell Stem Cell* 2012; **11**: 715-726 [PMID: 23122294 DOI: 10.1016/j.stem.2012.07.017]

145 **Bogliotti YS**, Wu J, Vilarino M, Okamura D, Soto DA, Zhong C, Sakurai M, Sampaio RV, Suzuki K, Izpisua Belmonte JC, Ross PJ. Efficient derivation of stable primed pluripotent embryonic stem cells from bovine blastocysts. *Proc Natl Acad Sci U S A* 2018; **115**: 2090-2095 [PMID: 29440377 DOI: 10.1073/pnas.1716161115]

146 **Li Y**, Wang X, Feng X, Liao S, Zhang D, Cui X, Gao F, Han C. Generation of male germ cells from mouse induced pluripotent stem cells in vitro. *Stem Cell Res* 2014; **12**: 517-530 [PMID: 24463497 DOI: 10.1016/j.scr.2013.12.007]

147 **Wang H**, Xiang J, Zhang W, Li J, Wei Q, Zhong L, Ouyang H, Han J. Induction of Germ Cell-like Cells from Porcine Induced Pluripotent Stem Cells. *Sci Rep* 2016; **6**: 27256 [PMID: 27264660 DOI: 10.1038/srep27256]

148 **Kobayashi T**, Zhang H, Tang WWC, Irie N, Withey S, Klisch D, Sybirna A, Dietmann S, Contreras DA, Webb R, Allegrucci C, Alberio R, Surani MA. Principles of early human development and germ cell program from conserved model systems. *Nature* 2017; **546**: 416-420 [PMID: 28607482 DOI: 10.1038/nature22812]

149 **Malaver-Ortega LF**, Sumer H, Jain K, Verma PJ. Bone morphogenetic protein 4 and retinoic acid trigger bovine VASA homolog expression in differentiating bovine induced pluripotent stem cells. *Mol Reprod Dev* 2016; **83**: 149-161 [PMID: 26660942 DOI: 10.1002/mrd.22607]

150 **Xie B**, Qin Z, Huang B, Xie T, Yao H, Wei Y, Yang X, Shi D, Jiang H. In vitro culture and differentiation of buffalo (Bubalus bubalis) spermatogonia. *Reprod Domest Anim* 2010; **45**: 275-282 [PMID: 19090820 DOI: 10.1111/j.1439-0531.2008.01281.x]

151 **Shah SM**, Singla SK, Palta P, Manik RS, Chauhan MS. Retinoic acid induces differentiation of buffalo (Bubalus bubalis) embryonic stem cells into germ cells. *Gene* 2017; **626**: 358-366 [PMID: 28526652 DOI: 10.1016/j.gene.2017.05.037]

152 **Zhu Y**, Hu HL, Li P, Yang S, Zhang W, Ding H, Tian RH, Ning Y, Zhang LL, Guo XZ, Shi ZP, Li Z, He Z. Generation of male germ cells from induced pluripotent stem cells (iPS cells): an in vitro and in vivo study. *Asian J Androl* 2012; **14**: 574-579 [PMID: 22504877 DOI: 10.1038/aja.2012.3]

153 **Cui T**, Li Z, Zhou Q, Li W. Current advances in haploid stem cells. *Protein Cell* 2020; **11**: 23-33 [PMID: 31004328 DOI: 10.1007/s13238-019-0625-0]

154 **Li Y**, Shuai L. A versatile genetic tool: haploid cells. *Stem Cell Res Ther* 2017; **8**: 197 [PMID: 28962667 DOI: 10.1186/s13287-017-0657-4]

155 **Bai M**, Wu Y, Li J. Generation and application of mammalian haploid embryonic stem cells. *J Intern Med* 2016; **280**: 236-245 [PMID: 27138065 DOI: 10.1111/joim.12503]

156 **Soto DA**, Ross PJ. Pluripotent stem cells and livestock genetic engineering. *Transgenic Res* 2016; **25**: 289-306 [PMID: 26894405 DOI: 10.1007/s11248-016-9929-5]

157 **Taft RA**, Low BE, Byers SL, Murray SA, Kutny P, Wiles MV. The perfect host: a mouse host embryo facilitating more efficient germ line transmission of genetically modified embryonic stem cells. *PLoS One* 2013; **8**: e67826 [PMID: 23844102 DOI: 10.1371/journal.pone.0067826]

158 **Laible G**, Alonso-González L. Gene targeting from laboratory to livestock: current status and emerging concepts. *Biotechnol J* 2009; **4**: 1278-1292 [PMID: 19606430 DOI: 10.1002/biot.200900006]

159 **Ohtsuka M**, Miura H, Nakaoka H, Kimura M, Sato M, Inoko H. Targeted transgenesis through pronuclear injection of improved vectors into in vitro fertilized eggs. *Transgenic Res* 2012; **21**: 225-226 [PMID: 21437715 DOI: 10.1007/s11248-011-9505-y]

160 **Tang L**, González R, Dobrinski I. Germline modification of domestic animals. *Anim Reprod* 2015; **12**: 93-104 [PMID: 27390591]

161 **Richt JA**, Kasinathan P, Hamir AN, Castilla J, Sathiyaseelan T, Vargas F, Sathiyaseelan J, Wu H, Matsushita H, Koster J, Kato S, Ishida I, Soto C, Robl JM, Kuroiwa Y. Production of cattle lacking prion protein. *Nat Biotechnol* 2007; **25**: 132-138 [PMID: 17195841 DOI: 10.1038/nbt1271]

162 **Fontes A**, Lakshmipathy U. Advances in genetic modification of pluripotent stem cells. *Biotechnol Adv* 2013; **31**: 994-1001 [PMID: 23856320 DOI: 10.1016/j.biotechadv.2013.07.003]

163 **Kou Z**, Kang L, Yuan Y, Tao Y, Zhang Y, Wu T, He J, Wang J, Liu Z, Gao S. Mice cloned from induced pluripotent stem cells (iPSCs). *Biol Reprod* 2010; **83**: 238-243 [PMID: 20427755 DOI: 10.1095/biolreprod.110.084731]

164 **Fan N**, Chen J, Shang Z, Dou H, Ji G, Zou Q, Wu L, He L, Wang F, Liu K, Liu N, Han J, Zhou Q, Pan D, Yang D, Zhao B, Ouyang Z, Liu Z, Zhao Y, Lin L, Zhong C, Wang Q, Wang S, Xu Y, Luan J, Liang Y, Yang Z, Li J, Lu C, Vajta G, Li Z, Ouyang H, Wang H, Wang Y, Yang Y, Liu Z, Wei H, Luan Z, Esteban MA, Deng H, Yang H, Pei D, Li N, Pei G, Liu L, Du Y, Xiao L, Lai L. Piglets cloned from induced pluripotent stem cells. *Cell Res* 2013; **23**: 162-166 [PMID: 23247628 DOI: 10.1038/cr.2012.176]

165 **Xie B**, Wang J, Liu S, Wang J, Xue B, Li J, Wei R, Zhao Y, Liu Z. Positive correlation between the efficiency of induced pluripotent stem cells and the development rate of nuclear transfer embryos when the same porcine embryonic fibroblast lines are used as donor cells. *Cell Reprogram* 2014; **16**: 206-214 [PMID: 24738969 DOI: 10.1089/cell.2013.0080]

166 **Zhou S**, Ding C, Zhao X, Wang E, Dai X, Liu L, Li W, Liu Z, Wan H, Feng C, Hai T, Wang L, Zhou Q. Successful generation of cloned mice using nuclear transfer from induced pluripotent stem cells. *Cell Res* 2010; **20**: 850-853 [PMID: 20548335 DOI: 10.1038/cr.2010.78]

167 **Petersen B**. Basics of genome editing technology and its application in livestock species. *Reprod Domest Anim* 2017; **52 Suppl 3**: 4-13 [PMID: 28815851 DOI: 10.1111/rda.13012]

168 **Wu G**, Bazer FW. Application of new biotechnologies for improvements in swine nutrition and pork production. *J Anim Sci Biotechnol* 2019; **10**: 28 [PMID: 31019685 DOI: 10.1186/s40104-019-0337-6]

169 **Zhao J,** Lai L, Ji W, Zhou Q. Genome editing in large animals: current status and future prospects. *Natl Sci Rev* 2019; 6: 402–420 [DOI: 10.1093/nsr/nwz013]

170 **Kumar D,** Kues WA Application of genome editing in farm animals. In: Genomics and biotechnological advances in veterinary, poultry, and fisheries. *Academic Press* 2019; 131-149 [DOI: 10.1016/B978-0-12-816352-8.00005-9]

171 **Li H,** Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. *Signal Transduct Target Ther* 2020; **5:** 1 [DOI: 10.1038/s41392-019-0089-y]

172 **Park KE**, Telugu BP. Role of stem cells in large animal genetic engineering in the TALENs-CRISPR era. *Reprod Fertil Dev* 2013; **26**: 65-73 [PMID: 24305178 DOI: 10.1071/RD13258]

173 **Gribben JG**. Stem cell transplantation in chronic lymphocytic leukemia. *Biol Blood Marrow Transplant* 2009; **15**: 53-58 [PMID: 19147079 DOI: 10.1016/j.bbmt.2008.10.022]

174 **Harding J**, Roberts RM, Mirochnitchenko O. Large animal models for stem cell therapy. *Stem Cell Res Ther* 2013; **4**: 23 [PMID: 23672797 DOI: 10.1186/scrt171]

175 **Volk SW**, Theoret C. Translating stem cell therapies: the role of companion animals in regenerative medicine. *Wound Repair Regen* 2013; **21**: 382-394 [PMID: 23627495 DOI: 10.1111/wrr.12044]

176 **Dehghan MM**, Baghaban Eslaminejad M, Motallebizadeh N, Ashrafi Halan J, Tagiyar L, Soroori S, Nikmahzar A, Pedram M, Shahverdi A, Kazemi Mehrjerdi H, Izadi S. Transplantation of Autologous Bone Marrow Mesenchymal Stem Cells with Platelet-Rich Plasma Accelerate Distraction Osteogenesis in A Canine Model. *Cell J* 2015; **17**: 243-252 [PMID: 26199903 DOI: 10.22074/cellj.2016.3724]

177 **Kastner A**, Gauthier P. Are rodents an appropriate pre-clinical model for treating spinal cord injury? Examples from the respiratory system. *Exp Neurol* 2008; **213**: 249-256 [PMID: 18675802 DOI: 10.1016/j.expneurol.2008.07.008]

178 **Kehinde EO**. They see a rat, we seek a cure for diseases: the current status of animal experimentation in medical practice. *Med Princ Pract* 2013; **22 Suppl 1**: 52-61 [PMID: 24217224 DOI: 10.1159/000355504]

179 **Gün G**, Kues WA. Current progress of genetically engineered pig models for biomedical research. *Biores Open Access* 2014; **3**: 255-264 [PMID: 25469311 DOI: 10.1089/biores.2014.0039]

180 **Cong X**, Zhang SM, Ellis MW, Luo J. Large Animal Models for the Clinical Application of Human Induced Pluripotent Stem Cells. *Stem Cells Dev* 2019; **28**: 1288-1298 [PMID: 31359827 DOI: 10.1089/scd.2019.0136]

181 **Plews JR**, Gu M, Longaker MT, Wu JC. Large animal induced pluripotent stem cells as pre-clinical models for studying human disease. *J Cell Mol Med* 2012; **16**: 1196-1202 [PMID: 22212700 DOI: 10.1111/j.1582-4934.2012.01521.x]

182 **Kurome M**, Geistlinger L, Kessler B, Zakhartchenko V, Klymiuk N, Wuensch A, Richter A, Baehr A, Kraehe K, Burkhardt K, Flisikowski K, Flisikowska T, Merkl C, Landmann M, Durkovic M, Tschukes A, Kraner S, Schindelhauer D, Petri T, Kind A, Nagashima H, Schnieke A, Zimmer R, Wolf E. Factors influencing the efficiency of generating genetically engineered pigs by nuclear transfer: multi-factorial analysis of a large data set. *BMC Biotechnol* 2013; **13**: 43 [PMID: 23688045 DOI: 10.1186/1472-6750-13-43]

183 **Bassols A**, Costa C, Eckersall PD, Osada J, Sabrià J, Tibau J. The pig as an animal model for human pathologies: A proteomics perspective. *Proteomics Clin Appl* 2014; **8**: 715-731 [PMID: 25092613 DOI: 10.1002/prca.201300099]

184 **Madeja ZE**, Pawlak P, Piliszek A. Beyond the mouse: non-rodent animal models for study of early mammalian development and biomedical research. *Int J Dev Biol* 2019; **63**: 187-201 [PMID: 31058296 DOI: 10.1387/ijdb.180414ap]

185 **Duranthon V**, Beaujean N, Brunner M, Odening KE, Santos AN, Kacskovics I, Hiripi L, Weinstein EJ, Bosze Z. On the emerging role of rabbit as human disease model and the instrumental role of novel transgenic tools. *Transgenic Res* 2012; **21**: 699-713 [PMID: 22382461 DOI: 10.1007/s11248-012-9599-x]

186 **Cebrian-Serrano A**, Stout T, Dinnyes A. Veterinary applications of induced pluripotent stem cells: regenerative medicine and models for disease? *Vet J* 2013; **198**: 34-42 [PMID: 24129109 DOI: 10.1016/j.tvjl.2013.03.028]

187 **Paterson YZ**, Kafarnik C, Guest DJ. Characterization of companion animal pluripotent stem cells. *Cytometry A* 2018; **93**: 137-148 [PMID: 28678404 DOI: 10.1002/cyto.a.23163]

188 **Kues WA**, Niemann H. The contribution of farm animals to human health. *Trends Biotechnol* 2004; **22**: 286-294 [PMID: 15158058 DOI: 10.1016/j.tibtech.2004.04.003]

189 **Klymiuk N**, Seeliger F, Bohlooly-Y M, Blutke A, Rudmann DG, Wolf E. Tailored Pig Models for Preclinical Efficacy and Safety Testing of Targeted Therapies. *Toxicol Pathol* 2016; **44**: 346-357 [PMID: 26511847 DOI: 10.1177/0192623315609688]

190 **Zhou L**, Wang W, Liu Y, Fernandez de Castro J, Ezashi T, Telugu BP, Roberts RM, Kaplan HJ, Dean DC. Differentiation of induced pluripotent stem cells of swine into rod photoreceptors and their integration into the retina. *Stem Cells* 2011; **29**: 972-980 [PMID: 21491544 DOI: 10.1002/stem.637]

191 **Amado LC**, Schuleri KH, Saliaris AP, Boyle AJ, Helm R, Oskouei B, Centola M, Eneboe V, Young R, Lima JA, Lardo AC, Heldman AW, Hare JM. Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. *J Am Coll Cardiol* 2006; **48**: 2116-2124 [PMID: 17113001 DOI: 10.1016/j.jacc.2006.06.073]

192 **Gandolfi F**, Vanelli A, Pennarossa G, Rahaman M, Acocella F, Brevini TA. Large animal models for cardiac stem cell therapies. *Theriogenology* 2011; **75**: 1416-1425 [PMID: 21463721 DOI: 10.1016/j.theriogenology.2011.01.026]

193 **Mazhari R**, Hare JM. Translational findings from cardiovascular stem cell research. *Trends Cardiovasc Med* 2012; **22**: 1-6 [PMID: 22940024 DOI: 10.1016/j.tcm.2012.05.017]

194 **Ye L**, Chang YH, Xiong Q, Zhang P, Zhang L, Somasundaram P, Lepley M, Swingen C, Su L, Wendel JS, Guo J, Jang A, Rosenbush D, Greder L, Dutton JR, Zhang J, Kamp TJ, Kaufman DS, Ge Y, Zhang J. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. *Cell Stem Cell* 2014; **15**: 750-761 [PMID: 25479750 DOI: 10.1016/j.stem.2014.11.009]

195 **Gu M**, Nguyen PK, Lee AS, Xu D, Hu S, Plews JR, Han L, Huber BC, Lee WH, Gong Y, de Almeida PE, Lyons J, Ikeno F, Pacharinsak C, Connolly AJ, Gambhir SS, Robbins RC, Longaker MT, Wu JC. Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by paracrine activation. *Circ Res* 2012; **111**: 882-893 [PMID: 22821929 DOI: 10.1161/CIRCRESAHA.112.269001]

196 **van der Spoel TI**, Jansen of Lorkeers SJ, Agostoni P, van Belle E, Gyöngyösi M, Sluijter JP, Cramer MJ, Doevendans PA, Chamuleau SA. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. *Cardiovasc Res* 2011; **91**: 649-658 [PMID: 21498423 DOI: 10.1093/cvr/cvr113]

197 **Guo J**, Wang H, Hu X. Reprogramming and transdifferentiation shift the landscape of regenerative medicine. *DNA Cell Biol* 2013; **32**: 565-572 [PMID: 23930590 DOI: 10.1089/dna.2013.2104]

198 **Holt WV**, Brown JL, Comizzoli P. Reproductive science as an essential component of conservation biology. *Adv Exp Med Biol* 2014; **753**: 3-14 [PMID: 25091903 DOI: 10.1007/978-1-4939-0820-2\_1]

199 **Brose U**, Hillebrand H. Biodiversity and ecosystem functioning in dynamic landscapes. *Philos Trans R Soc Lond B Biol Sci* 2016; **371**: [PMID: 27114570 DOI: 10.1098/rstb.2015.0267]

200 **Comizzoli P**, Mermillod P, Mauget R. Reproductive biotechnologies for endangered mammalian species. *Reprod Nutr Dev* 2000; **40**: 493-504 [PMID: 11140819 DOI: 10.1051/rnd:2000113]

201 **Mara L**, Casu S, Carta A, Dattena M. Cryobanking of farm animal gametes and embryos as a means of conserving livestock genetics. *Anim Reprod Sci* 2013; **138**: 25-38 [PMID: 23477753 DOI: 10.1016/j.anireprosci.2013.02.006]

202 **Comizzoli P**, Holt WV. Recent advances and prospects in germplasm preservation of rare and endangered species. *Adv Exp Med Biol* 2014; **753**: 331-356 [PMID: 25091916 DOI: 10.1007/978-1-4939-0820-2\_14]

203 **Arat S**, Caputcu AT, Akkoc T, Pabuccuoglu S, Sagirkaya H, Cirit U, Nak Y, Koban E, Bagis H, Demir K, Nak D, Senunver A, Kilicaslan R, Tuna B, Cetinkaya G, Denizci M, Aslan O. Using cell banks as a tool in conservation programmes of native domestic breeds: the production of the first cloned Anatolian Grey cattle. *Reprod Fertil Dev* 2011; **23**: 1012-1023 [PMID: 22127006 DOI: 10.1071/RD11026]

204 **Groeneveld LF**, Gregusson S, Guldbrandtsen B, Hiemstra SJ, Hveem K, Kantanen J, Lohi H, Stroemstedt L, Berg P. Domesticated Animal Biobanking: Land of Opportunity. *PLoS Biol* 2016; **14**: e1002523 [PMID: 27467395 DOI: 10.1371/journal.pbio.1002523]

205 **Selokar NL**, Sharma P, Krishna A, Kumar D, Kumar D, Saini M, Sharma A, Vijayalakshmy K, Yadav PS. Establishment of a Somatic Cell Bank for Indian Buffalo Breeds and Assessing the Suitability of the Cryopreserved Cells for Somatic Cell Nuclear Transfer. *Cell Reprogram* 2018; **20**: 157-163 [PMID: 29851497 DOI: 10.1089/cell.2017.0066]

206 **Mastromonaco GF**, González-Grajales LA, Filice M, Comizzoli P. Somatic cells, stem cells, and induced pluripotent stem cells: how do they now contribute to conservation? *Adv Exp Med Biol* 2014; **753**: 385-427 [PMID: 25091918 DOI: 10.1007/978-1-4939-0820-2\_16]

207 **Comizzoli P**, Holt WV. Implications of the Nagoya Protocol for genome resource banks composed of biomaterials from rare and endangered species. *Reprod Fertil Dev* 2016; **28**: 1145-1160[PMID: 26908038 DOI: 10.1071/RD15429]

208 **Comizzoli P**, Holt WV. Breakthroughs and new horizons in reproductive biology of rare and endangered animal species. *Biol Reprod* 2019; **101**: 514-525 [PMID: 30772911 DOI: 10.1093/biolre/ioz031]

209 **Oh HY**, Jin X, Kim JG, Oh MJ, Pian X, Kim JM, Yoon MS, Son CI, Lee YS, Hong KC, Kim H, Choi YJ, Whang KY. Characteristics of primary and immortalized fibroblast cells derived from the miniature and domestic pigs. *BMC Cell Biol* 2007; **8**: 20 [PMID: 17543094 DOI: 10.1186/1471-2121-8-20]

210 **Liu C**, Guo Y, Guan W, Ma Y, Zhang HH, Tang X. Establishment and biological characteristics of Luxi cattle fibroblast bank. *Tissue Cell* 2008; **40**: 417-424 [PMID: 18579172 DOI: 10.1016/j.tice.2008.04.005]

211 **Liu B**, Zhang H, Hao M, Yu S. Establishment and characterization of two fetal fibroblast cell lines from the yak. *In Vitro Cell Dev Biol Anim* 2012; **48**: 619-624 [PMID: 23161386 DOI: 10.1007/s11626-012-9559-z]

212 **Singh M**, Sharma AK. Outgrowth of fibroblast cells from goat skin explants in three different culture media and the establishment of cell lines. *In Vitro Cell Dev Biol Anim* 2011; **47**: 83-88 [PMID: 21108049 DOI: 10.1007/s11626-010-9373-4]

213 **Hochedlinger K**, Jaenisch R. Nuclear reprogramming and pluripotency. *Nature* 2006; **441**: 1061-1067 [PMID: 16810240 DOI: 10.1038/nature04955]

214 **Stanton MM**, Tzatzalos E, Donne M, Kolundzic N, Helgason I, Ilic D. Prospects for the Use of Induced Pluripotent Stem Cells in Animal Conservation and Environmental Protection. *Stem Cells Transl Med* 2019; **8**: 7-13 [PMID: 30251393 DOI: 10.1002/sctm.18-0047]

215 **Verma R**, Holland MK, Temple-Smith P, Verma PJ. Inducing pluripotency in somatic cells from the snow leopard (Panthera uncia), an endangered felid. *Theriogenology* 2012; **77**: 220-228, 228.e1-228.e2 [PMID: 22079579 DOI: 10.1016/j.theriogenology.2011.09.022]

216 **Ramaswamy K**, Yik WY, Wang XM, Oliphant EN, Lu W, Shibata D, Ryder OA, Hacia JG. Derivation of induced pluripotent stem cells from orangutan skin fibroblasts. *BMC Res Notes* 2015; **8**: 577 [PMID: 26475477 DOI: 10.1186/s13104-015-1567-0]

217 **Verma R**, Liu J, Holland MK, Temple-Smith P, Williamson M, Verma PJ. Nanog is an essential factor for induction of pluripotency in somatic cells from endangered felids. *Biores Open Access* 2013; **2**: 72-76 [PMID: 23514873 DOI: 10.1089/biores.2012.0297]

218 **Selvaraj V**, Wildt DE, Pukazhenthi BS. Induced pluripotent stem cells for conserving endangered species? *Nat Methods* 2011; **8**: 805-807 [PMID: 21959133 DOI: 10.1038/nmeth.1715]

219 **Hildebrandt TB**, Hermes R, Colleoni S, Diecke S, Holtze S, Renfree MB, Stejskal J, Hayashi K, Drukker M, Loi P, Göritz F, Lazzari G, Galli C. Embryos and embryonic stem cells from the white rhinoceros. *Nat Commun* 2018; **9**: 2589 [PMID: 29973581 DOI: 10.1038/s41467-018-04959-2]

220 **Fan N**, Lai L. Genetically modified pig models for human diseases. *J Genet Genomics* 2013; **40**: 67-73 [PMID: 23439405 DOI: 10.1016/j.jgg.2012.07.014]

221 **Moradi S**, Mahdizadeh H, Šarić T, Kim J, Harati J, Shahsavarani H, Greber B, Moore JB 4th. Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations. *Stem Cell Res Ther* 2019; **10**: 341 [PMID: 31753034 DOI: 10.1186/s13287-019-1455-y]

222 **Sun W**, Zheng W, Simeonov A. Drug discovery and development for rare genetic disorders. *Am J Med Genet A* 2017; **173**: 2307-2322 [PMID: 28731526 DOI: 10.1002/ajmg.a.38326]

223 **Hannoun Z**, Steichen C, Dianat N, Weber A, Dubart-Kupperschmitt A. The potential of induced pluripotent stem cell derived hepatocytes. *J Hepatol* 2016; **65**: 182-199 [PMID: 26916529 DOI: 10.1016/j.jhep.2016.02.025]

224 **Bruyneel AA**, McKeithan WL, Feyen DA, Mercola M. Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease? *Curr Opin Pharmacol* 2018; **42**: 55-61 [PMID: 30081259 DOI: 10.1016/j.coph.2018.07.003]

225 **Rowe RG**, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. *Nat Rev Genet* 2019; **20**: 377-388 [PMID: 30737492 DOI: 10.1038/s41576-019-0100-z]

226 **Paik DT**, Chandy M, Wu JC. Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. *Pharmacol Rev* 2020; **72**: 320-342 [PMID: 31871214 DOI: 10.1124/pr.116.013003]

227 **Argentati C**, Tortorella I, Bazzucchi M, Morena F, Martino S. Harnessing the Potential of Stem Cells for Disease Modeling: Progress and Promises. *J Pers Med* 2020; **10**: [PMID: 32041088 DOI: 10.3390/jpm10010008]

228 **Perleberg C**, Kind A, Schnieke A. Genetically engineered pigs as models for human disease. *Dis Model Mech* 2018; **11**: [PMID: 29419487 DOI: 10.1242/dmm.030783]

229 **Malhi PS**, Adams GP, Singh J. Bovine model for the study of reproductive aging in women: follicular, luteal, and endocrine characteristics. *Biol Reprod* 2005; **73**: 45-53 [PMID: 15744017 DOI: 10.1095/biolreprod.104.038745]

230 **Herath S**, Dobson H, Bryant CE, Sheldon IM. Use of the cow as a large animal model of uterine infection and immunity. *J Reprod Immunol* 2006; **69**: 13-22 [PMID: 16386311 DOI: 10.1016/j.jri.2005.09.007]

231 **Yapura J**, Mapletoft RJ, Pierson R, Singh J, Naile J, Giesy JP, Adams GP. A bovine model for examining the effects of an aromatase inhibitor on ovarian function in women. *Fertil Steril* 2011; **96**: 434-438.e3 [PMID: 21696721 DOI: 10.1016/j.fertnstert.2011.05.038]

232 **Kay MA**, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S, Fang B, Bellinger D, Finegold M, Thompson AR. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. *Proc Natl Acad Sci U S A* 1994; **91**: 2353-2357 [PMID: 8134398 DOI: 10.1073/pnas.91.6.2353]

233 **Wolfe JH**. Gene therapy in large animal models of human genetic diseases. Introduction. *ILAR J* 2009; **50**: 107-111 [PMID: 19293455 DOI: 10.1093/ilar.50.2.107]

234 **Chan AW**, Cheng PH, Neumann A, Yang JJ. Reprogramming Huntington monkey skin cells into pluripotent stem cells. *Cell Reprogram* 2010; **12**: 509-517 [PMID: 20936902 DOI: 10.1089/cell.2010.0019]

235 **Camnasio S**, Delli Carri A, Lombardo A, Grad I, Mariotti C, Castucci A, Rozell B, Lo Riso P, Castiglioni V, Zuccato C, Rochon C, Takashima Y, Diaferia G, Biunno I, Gellera C, Jaconi M, Smith A, Hovatta O, Naldini L, Di Donato S, Feki A, Cattaneo E. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. *Neurobiol Dis* 2012; **46**: 41-51 [PMID: 22405424 DOI: 10.1016/j.nbd.2011.12.042]

236 **Tu Z**, Yang W, Yan S, Guo X, Li XJ. CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases. *Mol Neurodegener* 2015; **10**: 35 [PMID: 26238861 DOI: 10.1186/s13024-015-0031-x]

237 **Karagiannis P**, Takahashi K, Saito M, Yoshida Y, Okita K, Watanabe A, Inoue H, Yamashita JK, Todani M, Nakagawa M, Osawa M, Yashiro Y, Yamanaka S, Osafune K. Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development. *Physiol Rev* 2019; **99**: 79-114 [PMID: 30328784 DOI: 10.1152/physrev.00039.2017]

238 **Tippett P**. Blood group chimeras. A review. *Vox Sang* 1983; **44**: 333-359 [PMID: 6349123 DOI: 10.1111/j.1423-0410.1983.tb03657.x]

239 **Wu J**, Greely HT, Jaenisch R, Nakauchi H, Rossant J, Belmonte JC. Stem cells and interspecies chimaeras. *Nature* 2016; **540**: 51-59 [PMID: 27905428 DOI: 10.1038/nature20573]

240 **Mascetti VL**, Pedersen RA. Human-Mouse Chimerism Validates Human Stem Cell Pluripotency. *Cell Stem Cell* 2016; **18**: 67-72 [PMID: 26712580 DOI: 10.1016/j.stem.2015.11.017]

241 **TARKOWSKI AK**. Mouse chimaeras developed from fused eggs. *Nature* 1961; **190**: 857-860 [PMID: 13775333 DOI: 10.1038/190857a0]

242 **Kobayashi T**, Yamaguchi T, Hamanaka S, Kato-Itoh M, Yamazaki Y, Ibata M, Sato H, Lee YS, Usui J, Knisely AS, Hirabayashi M, Nakauchi H. Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. *Cell* 2010; **142**: 787-799 [PMID: 20813264 DOI: 10.1016/j.cell.2010.07.039]

243 **Matsunari H**, Nagashima H, Watanabe M, Umeyama K, Nakano K, Nagaya M, Kobayashi T, Yamaguchi T, Sumazaki R, Herzenberg LA, Nakauchi H. Blastocyst complementation generates exogenic pancreas in vivo in apancreatic cloned pigs. *Proc Natl Acad Sci U S A* 2013; **110**: 4557-4562 [PMID: 23431169 DOI: 10.1073/pnas.1222902110]

244 **Yamaguchi T**, Sato H, Kato-Itoh M, Goto T, Hara H, Sanbo M, Mizuno N, Kobayashi T, Yanagida A, Umino A, Ota Y, Hamanaka S, Masaki H, Rashid ST, Hirabayashi M, Nakauchi H. Interspecies organogenesis generates autologous functional islets. *Nature* 2017; **542**: 191-196 [PMID: 28117444 DOI: 10.1038/nature21070]

245 **James D**, Noggle SA, Swigut T, Brivanlou AH. Contribution of human embryonic stem cells to mouse blastocysts. *Dev Biol* 2006; **295**: 90-102 [PMID: 16769046 DOI: 10.1016/j.ydbio.2006.03.026]

246 **Polzin VJ**, Anderson DL, Anderson GB, BonDurant RH, Butler JE, Pashen RL, Penedo MC, Rowe JD. Production of sheep-goat chimeras by inner cell mass transplantation. *J Anim Sci* 1987; **65**: 325-330 [PMID: 3610877 DOI: 10.2527/jas1987.651325x]

247 **Tachibana M**, Sparman M, Ramsey C, Ma H, Lee HS, Penedo MC, Mitalipov S. Generation of chimeric rhesus monkeys. *Cell* 2012; **148**: 285-295 [PMID: 22225614 DOI: 10.1016/j.cell.2011.12.007]

248 **Bożyk K**, Gilecka K, Humięcka M, Szpila M, Suwińska A, Tarkowski AK. Mouse↔rat aggregation chimaeras can develop to adulthood. *Dev Biol* 2017; **427**: 106-120 [PMID: 28499799 DOI: 10.1016/j.ydbio.2017.05.002]

249 **Jaszczak K**, Parada R, Guszkiewicz A. Cytogenetic study of some tissues and age-related changes in cell proportions in a goat-sheep chimera. *Cytogenet Cell Genet* 1999; **84**: 55-57 [PMID: 10343103 DOI: 10.1159/000015214]

250 **Bian G,** Qin Q, Feng G, Lu F, Shi D. A preliminary study on making interspecific chimeras between cattle and buffalo by aggregating blastomeres. *China Animal Husbandry & Veterinary Medicine* 2007; **34**: 44-46. Arrived from: http://en.cnki.com.cn/article\_en/cjfdtotal-gwxk200709013.htm

251 **Guo J**, Wu B, Li S, Bao S, Zhao L, Hu S, Sun W, Su J, Dai Y, Li X. Contribution of Mouse Embryonic Stem Cells and Induced Pluripotent Stem Cells to Chimeras through Injection and Coculture of Embryos. *Stem Cells Int* 2014; **2014**: 409021 [PMID: 25610470 DOI: 10.1155/2014/409021]

252 **Yang CM**, Gong XL, Qiu J, Tang HX, Gong ZJ, Huang SZ, Zeng F. Engraftment of genetically modified human amniotic fluid-derived progenitor cells to produce coagulation factor IX after in utero transplantation in mice. *Cell Biol Int* 2013; **37**: 420-429 [PMID: 23504762 DOI: 10.1002/cbin.10037]

253 **Vilarino M**, Rashid ST, Suchy FP, McNabb BR, van der Meulen T, Fine EJ, Ahsan SD, Mursaliyev N, Sebastiano V, Diab SS, Huising MO, Nakauchi H, Ross PJ. CRISPR/Cas9 microinjection in oocytes disables pancreas development in sheep. *Sci Rep* 2017; **7**: 17472 [PMID: 29234093 DOI: 10.1038/s41598-017-17805-0]

254 **Hai T**, Teng F, Guo R, Li W, Zhou Q. One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. *Cell Res* 2014; **24**: 372-375 [PMID: 24481528 DOI: 10.1038/cr.2014.11]

255 **Porsdam Mann S**, Sun R, Hermerén G. A framework for the ethical assessment of chimeric animal research involving human neural tissue. *BMC Med Ethics* 2019; **20**: 10 [PMID: 30683100 DOI: 10.1186/s12910-019-0345-2]

256 **Kwisda K**, White L, Hübner D. Ethical arguments concerning human-animal chimera research: a systematic review. *BMC Med Ethics* 2020; **21**: 24 [PMID: 32293411 DOI: 10.1186/s12910-020-00465-7]

257 **Slade P**. If you build it, will they eat it? Consumer preferences for plant-based and cultured meat burgers. *Appetite* 2018; **125**: 428-437 [PMID: 29501683 DOI: 10.1016/j.appet.2018.02.030]

258 **Post MJ**. Cultured meat from stem cells: challenges and prospects. *Meat Sci* 2012; **92**: 297-301 [PMID: 22543115 DOI: 10.1016/j.meatsci.2012.04.008]

259 **Scollan ND,** Greenwood PL, Newbold CJ, Yanez Ruiz DR, Shingfield KJ, Wallace RJ, Hocquette, JF. Future research priorities for animal production in a changing world. *Anim Prod Sci* 2011; **51(1):** 1-5 [DOI: 10.1071/AN10051]

260 **Arshad MS,** Javed M, Sohaib M, Saeed F, Imran A, Amjad Z. Tissue engineering approaches to develop cultured meat from cells: A mini review. *Cogent Food & Agri* 2017; **3:** 1320814 [DOI: 10.1080/23311932.2017.1320814]

261 **Genovese NJ**, Domeier TL, Telugu BP, Roberts RM. Enhanced Development of Skeletal Myotubes from Porcine Induced Pluripotent Stem Cells. *Sci Rep* 2017; **7**: 41833 [PMID: 28165492 DOI: 10.1038/srep41833]

262 **Yuan Y**. Capturing bovine pluripotency. *Proc Natl Acad Sci U S A* 2018; **115**: 1962-1963 [PMID: 29444863 DOI: 10.1073/pnas.1800248115]

263 **Yan X**, Zhu MJ, Dodson MV, Du M. Developmental programming of fetal skeletal muscle and adipose tissue development. *J Genomics* 2013; **1**: 29-38 [PMID: 25031653 DOI: 10.7150/jgen.3930]

264 **Chal J**, Pourquié O. Making muscle: skeletal myogenesis *in vivo* and *in vitro*. *Development* 2017; **144**: 2104-2122 [PMID: 28634270 DOI: 10.1242/dev.151035]

265 **Pimentel D**, Pimentel M. Sustainability of meat-based and plant-based diets and the environment. *Am J Clin Nutr* 2003; **78**: 660S-663S [PMID: 12936963 DOI: 10.1093/ajcn/78.3.660S]

266 **Stephens N**, Di Silvio L, Dunsford I, Ellis M, Glencross A, Sexton A. Bringing cultured meat to market: Technical, socio-political, and regulatory challenges in cellular agriculture. *Trends Food Sci Technol* 2018; **78**: 155-166 [PMID: 30100674 DOI: 10.1016/j.tifs.2018.04.010]

267 **Bhat ZF**, Morton JD, Mason SL, Bekhit AEA. Current and future prospects for the use of pulsed electric field in the meat industry. *Crit Rev Food Sci Nutr* 2019; **59**: 1660-1674 [PMID: 29393666 DOI: 10.1080/10408398.2018.1425825]

268 **Martin U**. Therapeutic Application of Pluripotent Stem Cells: Challenges and Risks. *Front Med (Lausanne)* 2017; **4**: 229 [PMID: 29312943 DOI: 10.3389/fmed.2017.00229]

269 **Doss MX**, Sachinidis A. Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications. *Cells* 2019; **8**: [PMID: 31052294 DOI: 10.3390/cells8050403]

270 **Kusumoto D**, Lachmann M, Kunihiro T, Yuasa S, Kishino Y, Kimura M, Katsuki T, Itoh S, Seki T, Fukuda K. Automated Deep Learning-Based System to Identify Endothelial Cells Derived from Induced Pluripotent Stem Cells. *Stem Cell Reports* 2018; **10**: 1687-1695 [PMID: 29754958 DOI: 10.1016/j.stemcr.2018.04.007]

271 **Cito M**, Pellegrini S, Piemonti L, Sordi V. The potential and challenges of alternative sources of β cells for the cure of type 1 diabetes. *Endocr Connect* 2018; **7**: R114-R125 [PMID: 29555660 DOI: 10.1530/EC-18-0012]

272 **Wu X**, Song M, Yang X, Liu X, Liu K, Jiao C, Wang J, Bai C, Su G, Liu X, Li G. Establishment of bovine embryonic stem cells after knockdown of CDX2. *Sci Rep* 2016; **6**: 28343 [PMID: 27320776 DOI: 10.1038/srep28343]

273 **Verma OP**, Kumar R, Nath A, Sharma M, Dubey PK, Kumar GS, Sharma GT. In vivo differentiation potential of buffalo (Bubalus bubalis) embryonic stem cell. *In Vitro Cell Dev Biol Anim* 2012; **48**: 349-358 [PMID: 22678753 DOI: 10.1007/s11626-012-9515-y]

274 **Pilichi S**, Rocca S, Dattena M, Pool RR, Mara L, Sanna D, Masala G, Manunta ML, Dore S, Manunta A, Passino ES. Sheep embryonic stem-like cells engrafted into sheep femoral condyle osteochondral defects: 4-year follow-up. *BMC Vet Res* 2018; **14**: 213 [PMID: 29954396 DOI: 10.1186/s12917-018-1532-y]

275 **Zhao Y**, Lin J, Wang L, Chen B, Zhou C, Chen T, Guo M, He S, Zhang N, Liu C, Liu M, Huang J. Derivation and characterization of ovine embryonic stem-like cell lines in semi-defined medium without feeder cells. *J Exp Zool A Ecol Genet Physiol* 2011; **315**: 639-648 [PMID: 22021232 DOI: 10.1002/jez.715]

276 **Cha HJ**, Yun JI, Han NR, Kim HY, Baek S, Lee SH, Lee J, Lee E, Park CK, Lee ST. Generation of embryonic stem-like cells from in vivo-derived porcine blastocysts at a low concentration of basic fibroblast growth factor. *Reprod Domest Anim* 2018; **53**: 176-185 [PMID: 29110378 DOI: 10.1111/rda.13088]

277 **Hou DR**, Jin Y, Nie XW, Zhang ML, Ta N, Zhao LH, Yang N, Chen Y, Wu ZQ, Jiang HB, Li YR, Sun QY, Dai YF, Li RF. Derivation of Porcine Embryonic Stem-Like Cells from In Vitro-Produced Blastocyst-Stage Embryos. *Sci Rep* 2016; **6**: 25838 [PMID: 27173828 DOI: 10.1038/srep25838]

278 **Zhang M**, Wang C, Jiang H, Liu M, Yang N, Zhao L, Hou D, Jin Y, Chen Q, Chen Y, Wang J, Dai Y, Li R. Derivation of novel naive-like porcine embryonic stem cells by a reprogramming factor-assisted strategy. *FASEB J* 2019; **33**: 9350-9361 [PMID: 31125263 DOI: 10.1096/fj.201802809R]

279 **Li X**, Zhou SG, Imreh MP, Ahrlund-Richter L, Allen WR. Horse embryonic stem cell lines from the proliferation of inner cell mass cells. *Stem Cells Dev* 2006; **15**: 523-531 [PMID: 16978056 DOI: 10.1089/scd.2006.15.523]

280 **Abavisani A,** Mckinnon AO, Tecirlioglu RT, Trounson AO, Guo J. Maintenance of horse embryonic stem cells in different conditions. *Iranian J Vet Res* 2010; **3:** 32 [DOI:10.22099/ijvr.2010.125]

281 **Tobias IC**, Brooks CR, Teichroeb JH, Villagómez DA, Hess DA, Séguin CA, Betts DH. Small-Molecule Induction of Canine Embryonic Stem Cells Toward Naïve Pluripotency. *Stem Cells Dev* 2016; **25**: 1208-1222 [PMID: 27392793 DOI: 10.1089/scd.2016.0103]

282 **Sandmaier SE**, Nandal A, Powell A, Garrett W, Blomberg L, Donovan DM, Talbot N, Telugu BP. Generation of induced pluripotent stem cells from domestic goats. *Mol Reprod Dev* 2015; **82**: 709-721 [PMID: 26118622 DOI: 10.1002/mrd.22512]

283 **Chen H**, Zuo Q, Wang Y, Song J, Yang H, Zhang Y, Li B. Inducing goat pluripotent stem cells with four transcription factor mRNAs that activate endogenous promoters. *BMC Biotechnol* 2017; **17**: 11 [PMID: 28193206 DOI: 10.1186/s12896-017-0336-7]

284 **Xu J**, Yu L, Guo J, Xiang J, Zheng Z, Gao D, Shi B, Hao H, Jiao D, Zhong L, Wang Y, Wu J, Wei H, Han J. Generation of pig induced pluripotent stem cells using an extended pluripotent stem cell culture system. *Stem Cell Res Ther* 2019; **10**: 193 [PMID: 31248457 DOI: 10.1186/s13287-019-1303-0]

285 **Setthawong P**, Phakdeedindan P, Tiptanavattana N, Rungarunlert S, Techakumphu M, Tharasanit T. Generation of porcine induced-pluripotent stem cells from Sertoli cells. *Theriogenology* 2019; **127**: 32-40 [PMID: 30639694 DOI: 10.1016/j.theriogenology.2018.12.033]

286 **Moro LN**, Amin G, Furmento V, Waisman A, Garate X, Neiman G, La Greca A, Santín Velazque NL, Luzzani C, Sevlever GE, Vichera G, Miriuka SG. MicroRNA characterization in equine induced pluripotent stem cells. *PLoS One* 2018; **13**: e0207074 [PMID: 30507934 DOI: 10.1371/journal.pone.0207074]

287 **Nishimura T**, Hatoya S, Kanegi R, Wijesekera DPH, Sanno K, Tanaka E, Sugiura K, Hiromitsu Tamada NK, Imai H, Inaba T. Feeder-independent canine induced pluripotent stem cells maintained under serum-free conditions. *Mol Reprod Dev* 2017; **84**: 329-339 [PMID: 28240438 DOI: 10.1002/mrd.22789]

288 **Gonçalves NJN**, Bressan FF, Roballo KCS, Meirelles FV, Xavier PLP, Fukumasu H, Williams C, Breen M, Koh S, Sper R, Piedrahita J, Ambrósio CE. Generation of LIF-independent induced pluripotent stem cells from canine fetal fibroblasts. *Theriogenology* 2017; **92**: 75-82 [PMID: 28237347 DOI: 10.1016/j.theriogenology.2017.01.013]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that there is no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** June 26, 2020

**First decision:** September 18, 2020

**Article in press:**

**Specialty type:** Cell Biology

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Berezin AE, Wang H **S-Editor:** Fan JR **L-Editor:** Webster JR **P-Editor:**


**Figure Legends**




**Figure 1** **Derivation of pluripotent stem cells from livestock and their differentiation properties**. IVF: *In vitro* fertilization; ES Cells: Embryonic stem cells; PA: Parthenogenetic activation; pES Cells: Parthenogenetically derived embryonic stem cells; SCNT: Somatic cell nuclear transfer; nES Cells: Nuclear transfer derived embryonic stem cells; IR: Induced reprogramming; iPS cells: Induced pluripotent stem cells.



**Figure 2** **Involvement of pluripotent stem cells in the reproductive cell cycle through reprogramming, differentiation and development**.



**Figure 3** **Outline of the production of transgenic livestock using pluripotent stem cells**. IR: Induced reprogramming; SCNT: Somatic cell nuclear transfer; IVF: *In vitro* fertilization; PA: Parthenogenetic activation; PSCs: Pluripotent stem cells; CRISPR: Clustered regularly interspaced short palindromic repeats; TALEN: Transcription activator-like effector nucleases; ZFN: Zinc finger nucleases.



**Figure 4** **Outline of the production of humanized organs in livestock by chimera formation.** OCT4: Octamer-binding transcription factor 4; SOX2: Sex determining region Y-box 2; KLF4: Kruppel-like factor 4; c-MYC: MYC Proto-Oncogene; hiPSC: Human induced pluripotent stem cells; piPSC: Porcine induced pluripotent stem cells; IR: Induced reprogramming; KO cells: Knock-out cells; SCNT: Somatic cell nuclear transfer.

**Table 1 Most recent examples of embryonic stem cells successfully generated from livestock**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Species** | **Embryonic stage** | **Culture medium and condition** | **Expression of pluripotency markers** | **Long-term culture (passage)** | **Karyotype** | ***In vitro* differentiation to EBs** | ***In vivo* differentiation to teratoma** | **Germ line transmission** | **Reference** |
| Cattle | CDX2-KD blastocysts | KO-DMEM, 2 mM glutamine, 1% MEM-NEAAs, 20 ng/mL hrFGF, 20 ng/mL hrLIF, 0.1 mM β–mercaptoethanol, 15% FBS + MEF under 37℃, 5% CO2 | Yes | 37 | Normal | Yes | Yes | No | [272] |
| Blastocysts | CTFR medium contains low fatty acid BSA, 20 ng/mL hFGF2, 2.5 μM IWR1 + MEFs under 37℃, 5% CO2 | Yes | > 70 | Normal | No | Yes | No | [145] |
| Buffalo | Blastocysts | KO-DMEM, 15% KSR, 2 mM L-glutamine, 50 μg/mL gentamicin sulfate, 1% MEM-NEAAs, 0.1 mM β-mercaptoethanol, 1000 IU/mL mLIF, 5 ng/mL FGF2 + BFF under 37℃, 5% CO2 | Yes | 135 | Normal | Yes | No | No | [20] |
| Blastocysts | DMEM, 20% FBS, 2 mM L-glutamine, 0.1 mM β-mercaptoethanol, 2% NEAA, 1% ITS, 50 μg/mL gentamycin sulfate, 30 ng/mL LIF, 40 ng/mL bFGF + BFF under 38.5℃, 5% CO2 | Yes | 15 | Normal | No | Yes | No | [273] |
| Ovine | Blastocysts | DMEM high glucose, 2 mM L-glutamine, 1 mM Na-Pyruvate, 0.1 mM β-mercaptoethanol, 0.1 mM NEAAs, 10 ng/mL LIF, 20 mg/mL insulin, 1000IU/mL penicillin, 10 mg/mL streptomycin + STO under 38.5℃, 5% CO2 | Yes | No | Normal | Yes | No | No | [274] |
| Blastocysts | DMEM/F12 supplemented with N2, B27, GSK3 inhibitor (CHIR99021), rhbFGF + OEF or MEF under 38.5℃, 5% CO2 | Yes | 30 | No | Yes | Yes | No | [275] |
| Caprine | Blastocysts | DMEM, 20% FCS, 1000 IU/mL mLIF, 1% NEAAs 0.1 mM β-mercaptoethanol, 2 mM l-glutamine + GFF under 38.5℃, 5% CO2 | Yes | 15 | Normal | Yes | No | No | [17] |
| Blastocysts | DMEM, 0.1 mM 2-mercaptoethanol, 0.1 mM MEM-NEAAs, 2 mM L-glutamine, 10% FBS, 1000 U/mL hLIF + GFF under 37℃, 5% CO2 | Yes | 120 | Normal | Yes | Yes | No | [16] |
| Porcine | Blastocysts | 1:1 ratio of 1. α-MEM medium supplemented with 10% KSR, 0.05 mM β-mercaptoethanol, 1% NEAAs, 1% antibiotic-antimycotic, 4 ng/mL EGF, 10 μL/mL 100 × ITS, 1000 U/mL mLIF, 2 ng/mL bFGF and, 2. DMEM/F-10-based medium supplemented with 15% heat-inactivated FBS, 0.2 mM β-mercaptoethanol, 1% NEAA, 1% antibiotic–antimycotic and 2 ng/mL bFGF  + MEFs under 37℃, 5% CO2 | Yes | 19 | Normal | Yes | No | No | [276] |
| Blastocysts | α-MEM, 20% KSR, 20 ng/mL bFGF, 20 ng/mL EGF, 10 ng/mL Activin-a, 1% ITS, 1 mM MEM-NEAAs, 55 μM β2-mercaptoethanol + STO at 38.5℃, 5% CO2 | Yes | 21 | Normal | Yes | Yes | No | [277] |
| Blastocysts | DMEM, 20% KSR and N2B27 medium, 1% NEAAs, 2 mM L-glutamine, 1% PS, 0.1 mM b-mercaptoethanol, 3 mM CHIR99021, 1 mM PD0325901, 2 mM SB, and 50 ng/mL vitamin C + MEFs under 38.5℃, 5% CO2 | Yes | 139 | Normal | Yes | Yes | No | [278] |
| Equine | Blastocysts | DMEM/F12, 15% FCS, 1000 U/mL hLIF, 15% FBS + MEF under 38.5℃, 5% CO2 | Yes | 28 | Normal | Yes | No | No | [279] |
| Blastocysts | KO-DMEM, 15% FBS, 0.1 mM NEAAs, 2 mM L-glutamine, 1% ITS, 100 μg/mL streptomycin, 100 IU/mL penicillin, 0.1 mM β-mercaptoethanol, hLIF, hbFGF + MEF under 38.5℃, 5% CO2 | Yes | 15 | No | No | No | No | [280] |
| Canine | Blastocysts | KO-DMEM/Ham’s F12, 15% KSR, 1 × GlutaMAX, 1 × NEAAs, R3IGF1, 0.1 mM 2-mercaptoethanol, 10 ng/mL hrLIF, 4 ng/mL rhFGF2, 0.5 μM, MEK inhibitor PD0325901, 3 μM GSK3β inhibitor CHIR99021 + MEFs under 37℃, 5% CO2 | Yes | -- | Normal | Yes | Yes | No | [281] |
|  | Blastocysts | KO-DMEM or DMEM/-12, 0.1 mM β-mercaptoethanol, 5 μM thymidine, 15 μM cytidine, 15 μM guanosine, 15 μM adenosine and 15 μM uridine nucleosides, 0.2 mM GlutaMax, 0.1 mM NEAAs, penicillin (100 IU/mL), streptomycin (50 μg/mL), 10 ng/mL hLIF, 4 ng/mL hbFGF, 15% FBS or KSR + MEFs under 37.5℃, 5% CO2. | Yes | 30 | Normal | Yes | Yes | No | [99] |

CDX2-KD: CDX2 gene knockdown; KO-DMEM: knockout Dulbecco's modified Eagle's medium; DMEM: Dulbecco's modified Eagle's medium; MEM-NEAA: Minimum Essential Medium-non-essential amino acids; hrFGF: Human recombinant ﬁbroblast growth factor; hrLIF: Human recombinant leukemia inhibitory factor; hFGF: Human ﬁbroblast growth factor; DMEM/F12: Dulbecco's modified Eagle's medium/nutrient mixture F-12;‎ FBS: Fetal bovine serum; MEF: Mouse embryonic fibroblast; mLIF: Mouse leukemia inhibitory factor; FGF2: Fibroblast growth factor 2; ITS: Insulin–transferrin–selenium; LIF: Leukemia inhibitory factor; bFGF: Basic growth factor; rhbFGF: Recombinant human basic ﬁbroblast growth factor; OEF: Ovine embryonic fibroblast; GFF: Goat fetal fibroblast; hLIF: Human leukemia inhibitory factor; PS: Penicillin-streptomycin; BSA: Bovine serum albumin; FCS: Fetal calf serum; KSR: Knockout serum replacer; EGF: Epidermal growth factor; BFF: Buffalo fetal fibroblast; STO: Sandos inbred mouse-derived 6-thioguanine-and ouabain-resistant; SB: SB431542 inhibitor.

**Table 2 Most recent examples of induced pluripotent stem cells successfully generated from livestock**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Species** | **Cell type** | **Culture medium and condition** | **Expression of pluripotency markers** | **Long-term culture (passage)** | **Karyotype** | ***In vitro* differentiation to EBs** | ***In vivo* differentiation to teratomas** | **Germline transmission** | **Reference** |
| Cattle | Fetal fibroblasts | DMEM/F-12, 20% KSR, 1 mM l-glutamine, 0.1 mM NEAAs, 0.1 mM mercaptoethanol, 100 U/mL penicillin, 100 μg/mL streptomycin, 8 ng/mL bFGF, 1000 U/mL hLIF on MEF at 37℃ and 5% CO2 | Yes | 40 | Normal | Yes | Yes | No | [58] |
| Fetal fibroblasts | KO-DMEM, 15% FBS, 2 mM L-glutamine, 1% NEAAs, 0.1 mM β-mercaptoethanol, 106 U/mL hLIF, 10 ng/mL bFGF on STO at 37℃ and 5% CO2 | Yes | 50 | Normal | Yes | Yes | No | [130] |
| Buffalo | Fetal fibroblasts | DMEM high glucose, 20% ESC-FBS, 2 mM l-glutamine, 1% NEAAs, 0.1 mM β-mercaptoethanol, 10 ng/mL bFGF, 10 ng/mL LIF on MEF at 37℃ and 5% CO2 | Yes | 10 | Normal | Yes | Yes | No | [65] |
| Fetal fibroblasts | DMEM/F-12, 20% KSR, 0.1 mM NEAAs, 1 mM L-glutamine, 0.1 mM mercaptoethanol, 100 U/mL penicillin, 100 μg/mL streptomycin, 10 ng/mL bFGF, 1000 U/mL hLIF on gelatine at 37℃ and 5% CO2 | Yes | 15 | Normal | Yes | No | No | [66] |
| Ovine | Embryonic fibroblasts | DMEM, 20% FBS, 1% ITS, 0.1 mM 2-β mercaptoethanol, 1 mM NEAAs, 2 mM glutamine, 4 ng/mL bFGF, 1000 U/mL mLIF on MEFs at 37℃ and 5% CO2 | Yes | 17 | Normal | Yes | Yes | Yes (formation of ICM in tetraploid) | [50] |
| Embryonic fibroblasts | KO-DMEM, KSR, 0.1 mM NEAAs, 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol, 8 ng/mL hFGF2, 1000 U/mL mLIF on SNL at 37℃ and 5% CO2 | Yes | 23 | Normal | Yes | Yes | Yes (live-born chimeric lambs) | [67] |
| Caprine | Fetal fibroblasts | DMEM/F12, 20% KSR, 1 mM L-glutamine, 0.1 mM 2-mercaptoethanol, 1% NEAAs, 2% sodium bicarbonate solution, 1000 IU/mL 2i/LIF, 4 ng/mL bFGF on STO at 37℃ and 5% CO2 | Yes | 30 | Normal | Yes | Yes | No | [282] |
| Embryonic fibroblasts | KO-DMEM, 20% KSR, 1% NEAA, 1% L-glutamine, 0.1 mM EAA, 1% penicillin /streptomycin, 10 ng/mL FGF2 on GEF at 37℃ and 5% CO2 | Yes | 22 | Normal | Yes | No | No | [283] |
| Porcine | Embryonic fibroblasts and microvascular pericyte cells | LCDMV medium contains 50% neurobasal medium, 50% DMEM/F12, 1 × N2, 0.5 × B27, 5% KSR, 10 ng/mL LIF, 1 μM CHIR99021, 2 μM (S)-(+)-dimethindene maleate, 2 μM minocycline hydrochloride, 40 μg/mL vitamin C on MEF at 37℃ and 5% CO2 | Yes | 28 | Normal | Yes | Yes | Yes  (chimeric formation in post-implantation pig conceptuses) | [284] |
| Sertoli cells | DMEM/F12, 10% KSR, 10% FBS, 1 mM l-glutamine, 1 mM antibiotic, 1% NEAAs, 0.1 mM β-mercaptoethanol, 10 ng/mL bFGF, 10 ng/mL hLIF on MEF at 37℃ and 5% CO2 | Yes | 50 | Normal | Yes | Yes | No | [285] |
| Equine | Fetal fibroblasts | DMEM/F12, 20% KSR, 10 ng/mL bFGF, 1% penicillin/streptomycin, 10 ng/mL hLIF on MEF at 37℃ and 5% CO2 | Yes | 25 | -- | Yes | No | No | [286] |
| Fetal fibroblasts | DMEM, 20% FBS or KO-DMEM, 20% KSR, 2 mM l-glutamine, 0.1 mM β-mercaptoethanol, 0.1 mM MEM- NEAAs, 1% penicillin–streptomycin, 8 ng/mL hbFGF, 1000 U/mL hLIF on SNL at 37℃ and 5% CO2 | Yes | 30 | Normal | Yes | Yes | No | [61] |
| Canine | Embryonic fibroblasts | Serum-free N2B27-based medium, 4 ng/mL hbFGF on MEF at 37℃ and 5% CO2 | Yes | 50 | Normal | Yes | No | No | [287] |
| Fetal fibroblasts | KO-DMEM/F12, 20% KSR, 2 mM L-glutamine, 0.1 mM NEAAs, 0.1 mM β-mercaptoethanol, 0.1 mM bFGF on MEF at 37℃ and 5% CO2 | Yes | 15 | Normal | Yes | Yes | No | [288] |

DMEM: Dulbecco's modified Eagle's medium; KO-DMEM: Knockout Dulbecco's modified Eagle's medium; DMEM/F12: Dulbecco's modified Eagle's medium/nutrient mixture F-12;‎ NEAAs: Non-essential amino acids; bFGF: Basic fibroblast growth factor; hLIF: Human leukemia inhibitory factor; MEF: Mouse embryonic fibroblast; KSR: Knock-out serum replacement; FBS: Fetal bovine serum; LIF: Leukemia inhibitory factor; ESC-FBS: Embryonic stem cells-fetal bovine serum; ITS: Insulin–transferrin–selenium; mLIF: Mouse leukemia inhibitory factor; hFGF2: Human fibroblast growth factor 2; EAAs: Essential amino acids; hbFGF: Human basic fibroblast growth factor; STO: Sandos inbred mouse-derived 6-thioguanine-and ouabain-resistant.